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ABSTRACT OF DISSERTATION
IL-2 and Antisense TGF-pi Gene Therapy of the FI238 Tumor
and Analysis of TGF-p Receptors
by
Azim Moiz Mohamedali
Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, June 2001
Dr. James D. Kettering, Chairperson
Transforming growth factor-beta (TGF-p) belongs to a family of
immunosuppressive cytokines, capable of regulating macrophages, T, B and NK
cells. We have detected the TGF-p transcript being synthesized by H238 cells.
This is herpes simplex-Type2 transformed murine fibrosarcoma cell line. The
amount of TGF-p formed/106 cells was >2000pg/ml. Previous attempts to control
H238 tumorigenicity had sub-optimal efficacies. In addition, studies had shown
that the FI238 cell line was not responsive to TGF-p. This project was an attempt
to develop an improved modality to reduce H238 tumorigenicity and investigate
potential abnormalities in expression of TGF-p receptors in the H238 cell line.
We created expression plasmids encoding transgenes for murine IL-2 and
antisense TGF-p and stably transfected H238 cells to create populations/clones
of H238 cells expressing these transgenes. In vitro, expression analysis using
ELISA and RT-PCR showed that H238 cells are capable of expressing functional
IL-2 and, in addition, antisense transfected H238 cells showed a significant
decrease in TGF-p production. The ultimate test, was to evaluate the
tumorigenicity of these stable transfected cells in an immunocompetent BALB/c
x

host, in comparison to wild type H238 cells. Mice injected with wild type and
control H238 cells, showed a 80 - 100% tumor incidence. Mice injected with
either antisense TGF-p or murine IL-2 transfected H238 cells showed almost no
tumor incidence (0-20%). Mitogen stimulation of splenocytes from tumor bearing
and non tumor bearing animals showed significant differences. Splenocytes from
non tumor bearing animals displayed a higher stimulation index than from tumor
bearing animals, probably alluding to lower amounts of tumor derived systemic
TGF-p.
The non-responsiveness of H238 cells to TGF-p was also confirmed. Our
results corroborated Uhm, at al (1993), whereby the authors reported similar
results. To evaluate this further, we hypothesized that a defect within the TGF-p
receptors may be the cause of this inert response. Total H238 RNA was
exctracted and mRNA for TGF-p receptors was amplified using primers specific
to the Type 1 and Type 2 TGF-p receptors, these were sequenced to confirm
their identity. Our sequence analysis concluded that the TGF-p receptors on
H238 cells were essentially normal with no critical mutations which would
validate either splicing or truncated products. Protein expression was confirmed
using Western blot analysis. Whole cell lysate was also resolved into membrane
and cytosolic fractions, and these probed with for the type 1 or the type2
receptor. In comparision, to positive cell lysate controls for these receptors, H238
cell lysates showed a comparitively less amount of receptor expression.
Receptor expression was further quantitated using a laser scanning cytometer.

xi

Using this procedure, H238 cells showed approximately 50% less expression of
the type 2 TGF-p receptor than the type 1 TGF-p receptor. Cytochemical staining
for the receptors showed little membrane puncate staining, however, distinct
staining was observed in the cytosolic regions of the cells. The lack of pucntate
staining may be explained by either the relatively very few numbers of TGF-p
receptors expressed/cell or there may be defects in the glycosylation and
receptor trafficking. In addtion, the different ratios of the type 1 and type 2
receptor expression may also account for the inertness of H238 cells to TGF-p.
This has been shown to be present in other tumor models and may explain the
non responsiveness of FI238 cells to TGF-p.

xii

INTRODUCTION
A. Cancer and different evasive mechanisms
Within the next decade or two, cancer is likely to become the leading
cause of death in the United States (Bishop, 1997). However, the exact process
by which cancer cells arise and develop into malignant disease continues to be a
perplexing question to scientists. Control over cell proliferation is essential for
the survival of a multi-cellular organism, yet relatively little is known about the
mechanism of this control.
Cancer cells grow under conditions that are insufficient for normal cell
proliferation (Padre, 1987). The escape of cancer cells from extracellular growth
control can be demonstrated by their ability to grow in culture conditions using
low serum concentrations and in the absence of growth factors, such as
epidermal growth factor (EOF). Ovarian cancer cells may grow in suspension,
without requiring attachment to an extracellular matrix. Cancer cells, in vivo, can
occur spontaneously or can be induced with carcinogens or viruses carrying
transforming genes (viral oncogenes). The ras oncogene (Padre, 1989) and the
tumor suppressor protein, p53 (Hollstein et ai, 1991) are factors implicated in
this scenario. The progression of cancer is associated with the presence of
growth factors that may selectively stimulate the cancer cells to grow at a higher
rate than normal cells. Growth factors present in both adult and embryonic cells,
are released by many, if not all, cells in culture (Goustin et al., 1986).
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Loss of a requirement for specific growth factors is a common finding in
many types of cancer cells. This could be mediated by (a) the activation of
autologous growth factor synthesis (autocrine activation), (b) synthesis of an
autologous growth factor receptor or (c) activation of a post-receptor pathway
that bypasses the growth factor requirement (Kaplan et al., 1982). Viruses and
their association with oncogenes, which in turn are often related to growth
factors, have played an important role in tumorigenesis.
Although viruses have been conclusively implicated as etiological agents
in many animal tumors, it has been extremely difficult to characterize their role in
human disease. One of the first and most convincing studies demonstrated the
permanent transfer of genetic information to code for virus enzyme and antigen.
Davis (1974), demonstrated that mouse L cells deficient in the enzyme thymidine
kinase can be converted to positive thymidine kinase (TK) phenotype by means
of Herpes simplex virus Type 1 (HSV-1), which had been inactivated with ultra
violet light. The new TK in the cells had the distinct properties of the herpes virus
type used to infect the cells (Ogino and Rapp, 1971). Furthermore, the viral DNA
coding for the TK enzyme remains stably associated with the cells’ progeny and
DNA fragments of approximately 10% of the Herpes simplex virus Type 2 (HSV2) genome can be detected with DNA:DNA hybridization. Unfortunately, the L
cells used were malignant prior to HSV infection; thus, the malignant properties
could not be definitively attributed to HSV infection. Subsequently, hamster
embryo fibroblast (HEF) cultures were transformed in vitro after infection with
UV-inactivated HSV-2. Tumors were detectable 10-16 weeks after inoculation in
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inbred hamsters. The original cell line and tumor-derived lines had HSV-2
specific antigens (Duff and Rapp, 1971a; Duff and Rapp, 1971b) as shown by
neutralization studies against HSV-1 and HSV-2, using sera from the tumor
bearing animals. Work from other laboratories has conformed the initial
transformation studies relating the oncogenic potential of HSV. Kutinova, et al
(1973) used inactivated HSV to convert a weakly malignant established hamster
cell line to a highly malignant state. Daral and Munk (1973) demonstrated that
human embryonic lung cells infected with HSV and maintained at non-permissive
temperatures became transformed and synthesized viral antigens.
An apparent increased risk of cancer due to herpes simplex virus genital
infection (Rawls et al., 1969) focused many researchers on this agent. The
detection of viral antigens (Aurelian, 1973, Dreesman et al., 1980), herpes virus
RNA (McDougall et al., 1980, Eglin et al., 1981) and DMA (Frenkel, et al, 1972)
provided evidence of a strong association between HSV-2 and squamous cell
carcinoma of the uterine cervix. Studies also showed that HSV-1 and HSV-2,
when inactivated, were still capable of transforming rodent cells to a malignant
phenotype (Boyd and Orme, 1975). More recently, papilloma viruses are thought
to be more significantly involved as etiologic agents in cervical carcinomas (Nair
et al., 2000; Dillner, 2000). However, this issue continues to be surrounded by
great controversy.
Most work with viruses and cancer has involved retroviruses capable of
acquiring cellular genetic sequences. The viral oncogene sequences are almost
identical to sequences in genomic DMA. This finding indicates that cellular DMA
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contains genes that have the potential to cause cancer when transduced into
retroviruses (Franks and Teich, 1986). Viral oncogenes of DNA viruses,
however, are totally different from the retrovirus oncogenes and lack sequence
homology with known cellular proto-oncogenes. In the DNA virus HSV-2, the
transforming region of DNA has been located at map units 0.58 to 0.62 (Fields, et
al, 1986). DNA viral oncogenes induce essential enzymes that activate the
resting host cells’ machinery to promote viral DNA replication or down regulate
the hosts immune system.
The most extensively studied immunosuppressive molecules secreted by
tumors are transforming growth factor-beta (TGF-p), interleukin 10 (IL-10), and
prostaglandin E2, (PGE-2).
B. Transforming Growth Factor Beta
TGF-p exists in at least three isoforms, known as TGF-p1, TGF-p2 and
TGF-p3. Their amino acid sequences display homologies on the order of 70-80
percent. TGF-p1 is the most prevalent form and is found almost ubiquitously,
while the other isoforms are expressed in a more limited spectrum of cells and
tissues (Massague, 1998).
The biologically active forms of TGF-p isoforms are disulfide-linked
homodimers. Disulfide-linked heterodimers of TGF isoforms have been reported
also. The heat and acid-stable monomeric subunits have a length of 112 amino
acids (aa). The isoforms of TGF-p arise by proteolytic cleavage of the
carboxyterminal ends from longer precursors (TGF-p1: 390 aa, TGF-p2: 412 aa,
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TGF-p3: 412 aa) (Oklu and Hesketh, 2000). Isoforms isolated from different
species are evolutionarily closely conserved and have sequence identities on the
order of 98%. Mature human, chicken, porcine, simian and bovine TGF-p1 are
identical and differ from murine TGF-p1 in a single amino acid position (Derynck
et al., 1986).
Almost all forms of TGF-p are released as biologically inactive forms
known as latent-TGF (L-TGF). Latent forms are complexes of TGF-p, an amino
terminal portion of the TGF-p precursor designated TGF-latency associated
peptide (TGF-LAP), and a specific binding protein, known as latent TGF binding
protein (LT-BP). Biologically active TGF-p results after dissociation from the LAP
complex. The activation mechanism of L-TGF in vivo is unclear, though it has
been postulated to involve direct cell-to-cell contacts, proteases - specifically
plasmin, and has recently also been shown to be mediated by transglutaminases
(Oklu and Hesketh, 2000).
The biological activities of TGF-p are not species-specific. The various
TGF-p isotypes share many biological activities, and their actions on cells are
qualitatively similar in most cases, although there are a few examples of distinct
activities (Massague, 1998). The most pronounced difference in the TGF-p
isoforms are their spatially and temporally distinct expression of both the mRNAs
and proteins in developing tissues, regenerating tissues, and in pathologic
responses. TGF-p isoforms have differential functions in epidermal
carcinogenesis, such that TGF-p1 is associated with the more differentiated
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state, TGF-p2 with highly malignant and invading cells, and TGF-p3 with tumor
stroma formation and angiogenesis (Gold etal., 2000). Furthermore, the
expression of TGF-p’s by both early- and late-stage tumors implies that the
isoforms may have distinct functions at different stages of malignancy, supporting
their dual role in carcinogenesis (Gold et a!., 2000).
The TGF-p family is an example of immuno-suppressive cytokines that
may be activated by viral oncogenes. TGF-p modulates fundamental elements
necessary for the initiation and maintenance of T-cell activation and function
(Roszman et al., 1991). TGF-p inhibits the generation of lymphokine activated
killer (LAK) cells (Naganuma et al., 1996), mitogen-induced T cell responses
(Knoefel et al., 1997), interferon-activated natural killer (NK) cell activity (Yoon et
al., 1998) and immunoglobin secretion by B cells (Ohtsuka et al., 1999) in vitro.
This effect is thought to be generated through a feedback mechanism involving
multiple effector cells of the immune system (Ruffini et al., 1993; Fontana et al.,
1989; Ranges et al., 1987; Tsunawaki et al., 1988) (Fig 1). In addition, TGF-p
appears to suppress the immune system by impairing high-affinity IL-2 receptor
function and expression (Roszman etal., 1991; Ruffini etal., 1993; Smith, 1993;
Tigges et al., 1989). Therefore, the ability of any malignant or transformed cell to
produce this cytokine potentially provides an ideal mechanism to inhibit a host’s
immune system by subverting the lymphokine activated killer (LAK) cell
response. TGF-p also influences the secretion of immunoglobulins by B-
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Fig. 1 Pleuripotent effect of TGF-p on the
immune system and surrouding tissue.
Positive influences are indicated by (+) and
negative inlfluences are indicated by (-).
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lymphocytes. The synthesis of IgG and IgM by B-lymphocytes is inhibited while
the synthesis of IgA is stimulated (Lehman and Edmiston, 1999). TGF-p
modulates the synthesis of acute phase proteins by hepatocytes and inhibits the
Adreno Corticotropic Hormone (ACTH)-induced synthesis of cortisol (Chambaz
et al., 1996). TGF-p1 is the most potent known chemokine for neutrophils. It
specifically attracts neutrophils at concentrations of 1 fM and is, therefore,
approximately 150,000-fold more potent than Formyl-Met-Leu-Phe (FMLP) motif
(Parekh et al., 1994).
TGF-(3 is the most potent known growth inhibitor for normal and
transformed epithelial cells, endothelial cells, fibroblasts, neuronal cells, lymphoid
cells, hepatocytes, and keratinocytes and other hematopoietic cell types
(Ottmann and Pelus, 1988). TGF-p inhibits the synthesis of granulocyte/
macrophage-colony stimulating factor (GM-CSF), interleukin-3 (IL-3), and the
expression of the receptor for granulocyte-colony stimulating factor (G-CSF)
(Besse et al., 2000). It also inhibits the growth of immature hematopoietic
progenitor cells induced by IL-3, GM-CSF, and monocyte-colony stimulating
factor (M-CSF), in particular growth of colony forming unit-granulocyte
/erythroid/macrophage/megakaryocyte (CFU-GEMM). TGF-p also inhibits
megakaryocytopoiesis (precursor to platelets). In many cell types, TGF-p
antagonizes the biological activities of platelet derived growth factor (PDGF),
alpha and beta fibroblast growth factors (ocFGF and pFGF) (McCartney-Francis
et al., 1990). TGF-p1 and TGF-p2 inhibits the proliferation of lymphocytes
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induced by IL-1 (Wahl et ai, 1988). The latent form of TGF-p is also a strong
inhibitor of erythroleukemia cell lines (Ottmann and Pelus, 1988).
The extent of growth inhibition induced by TGF-p depends on the cell
type, concentration of TGF-p, and the presence of other factors. Epithelial cells of
the lung and keratinocytes are arrested in their growth (Hashimoto, 2000). The
growth-inhibitory activities of TGF-p have been shown to be abolished by
hepatocyte growth factor (HGF) (Harrison et ai, 2000). At low concentrations,
TGF-p is a growth inhibitor for smooth muscle cells, fibroblasts, and
chondrocytes, whereas, at higher concentrations, TGF-p stimulates the growth
of these cells. This bimodal activity is mediated, in part, by PDGF (Janat and
Liau, 1992 and Oates et ai, 1995). The synthesis and secretion of which is
stimulated by low concentrations of TGF-p, while higher concentrations of TGF-p
lower the expression of the PDGF receptors and, hence, diminish the biological
effects of PDGF (Bronzert et ai, 1990).
Although TGF-p inhibits the growth of endothelial cells, it promotes
angiogenesis in several bioassays. Angiogenesis is the process by which solid
tumors vascularize with blood vessels. It has been suggested that overproduction
of TGF-p1 by tumor cells can contribute to neovascularization/angiogenesis and
may help promote tumor development in vivo (Wikstrom et ai, 1998). In addition,
TGF-p is an autocrine growth modulator for malignant gliomas, including
fibroblasts and osteoblasts in vivo and in vitro (Jennings and Pietenpol, 1998).
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TGF-p stimulates the synthesis of the major matrix proteins, including
collagen, proteoglycans, glycosaminoglycans, fibronectin, integrins,
thrombospondin, osteonectin and osteopontin. It inhibits their degradation mainly
by preventing the synthesis of neutral metalloproteinases and by increasing the
synthesis of protease inhibitors (Yabushita et al., 2000). TGF-p1 modulates the
interaction of tumor cells with the cellular matrix. It is, therefore, probably also
involved in metastatic processes together with other protein factors.
C. Mechanisms of Action and Signal Transduction
TGF-p exerts its effects by binding to and activating specific receptors
located on the cell membrane. Two signaling receptors, termed type I (TGF-pRI)
and type II receptors (TGF-pRII), have been cloned (Ebner et al., 1993 and
Derynck, 1994). Each type possesses an ectodomain, a single transmembrane
portion and a serine/threonine kinase domain in its cytoplasmic region. Recent
molecular and cytoplasmic analysis have shown that the type I receptor can only
recognize TGF-p that is already bound to the type II receptor (Yamashita et al.,
1994), and suggested that the formation of a ligand-induced heterodimer
involving both type I and type II receptors is required for signaling (Vivien et al.
1995).
The TGF-p type II receptor binds activated ligand in the free medium, thus
activating its kinase domain. Unlike the type II receptor, the type I receptor is
unable to bind the ligand directly from the medium. However, it can recognize the
ligand bound to type receptor II and form a very stable ternary (Involving three
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variables) complex. Recruitment of type receptor I into the complex results in
type receptor I phosphorylation (Fig 2). This phosphorylation occurs in the
Ser/Thr residues in the glycine-serine rich (GS) domain and is not an auto
phosphorylation, but phosphorylation by the type receptor II. The type receptor I
is catalytically inactive because of a wedge shaped GS region inserted into the
kinase domain, disabling the catalytic center. In the ligand-induced receptor
complex, type receptor II phosphorylates the GS region, resulting in activation of
the receptor I kinase. This, then, generates an activated receptor complex. The
formation of this complex is tightly correlated with signaling. Cells defective in
one or the other receptor are refractory to any effects of TGF-p (reviewed in
Massague, 1998).
The Smad proteins are a family of transcription factors found in
vertebrates, insects and nematodes (Fig 3). The Smads are currently the only
TGF-p receptor substrates with a demonstrated ability to propagate signal. The
activated complex recognizes the Smad group known as receptor-activated
Smads (R-Smads). These include Smad2 and Smad3. The R-Smads consist of
two conserved domains that form globular structures separated by a linker
region. The N-terminal MH1 domain has DNA binding activity whereas the Cterminal MH2 domain drives translocation into the nucleus and has
transcriptional regulatory activity (Fig 2). En route to the nucleus, R-Smads
associate with members of a second group known as Co-Smads. Their
interaction with R-Smads is primarily mediated by the MH2 domain contacts. The
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Fig. 2 The TGF-p signal transduction pathway.
TGF-p ligand is activated outside the cell and binds
to TGF-pR2. Transphosphorylation of TGF-pR1 by
R2 activates the internal signal transduction signaling
allowing SMAD signaling. The Smad proteins get
translocated into the nuclueus influencing the
upregualtion or down regulation of different proteins
by controlling transcription (Pasche, 2001).
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Fig 3 Sequence alignments of the SAD, TOWER
and C-terminal tail regions of SMAD proteins.
Smad4 isoforms from human, rat, mouse, Xenopus
(XENO), medea (MEDEA) and C. elegans (CELEG)
are underlined. The conserved residues of Smad4
sequences are shown in red; the invariable residues in
all SMAD proteins are in green. The Smadl, Smad2,
Smad3, Smad5, Smad6 and Smad7 sequences are
from human. The SmadS sequence is from rat.
Secondary structures are indicated by # (helix), ~
(loop), and =:> (strand). (Qin et al, 1999)
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Co-Smads are shared by all R-Smads and are required for the formation of
functional transcription complexes. Both the R-Smad and the Co-Smads may
participate in DNA binding and recruitment of transcriptional cofactors (Fig 2)
(reviewed in Miyazono, 2000).
D. TGFp and Cancer
Although TGF-p is a potent growth inhibitor of epithelial tissues, it is both a
suppressor and a promoter of tumorigenesis. TGF-p has a tumor suppression
function that is lost in many tumor-derived cell lines (Reiss, 1997, reviewed in
Gold, 1999). It has been estimated that nearly all pancreatic cancers (Goggins et
al., 1998, Villanueva ef a/., 1998) and colon cancers (Grady etal., 1999) have
mutations disabling a component of the TGF-p signaling pathway. Some of these
mutations occur in the TGF-p receptors, Smad4 or Smad2 (reviewed by de
Caestecker et al., 2000). Others may occur in untested or unknown components
of the signaling pathway. Transgenic expression of a dominant-negative TGFpRII construct in the mammary gland or the epidermis diminished epithelial
responsiveness to TGF-p and increased the tumor incidence in these tissues
when the mice were challenged with a carcinogen (Bottinger et al., 1997). On the
other hand, TGF-p exacerbates the malignant phenotype of transformed and
tumor-derived cells in experimental systems, and there is some evidence that it
may be doing the same in human cancer. Tumor-derived TGF-p could contribute
to tumor growth indirectly by suppressing immune surveillance or stimulating
production of angiogenic factors. However, TGF-p can also act directly on cancer
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cells to foster tumorigenesis. Tumor cells that have selectively lost their growthinhibitory responsiveness to TGF-p but retain an otherwise functional TGF-p
signaling pathway may exhibit enhanced migration and invasive behavior in
response to TGF-p stimulation (Oft et ai, 1998; Yin et al., 1999). Expression of
dominant-negative TGF-pRII in human mammary adenocarcinoma cells reduced
the size and number of bone metastases generated in athymic mice (Yin et al.,

1999).
TGF-p signaling could promote tumor cell metastasis in many different
ways (McEarchern et al., 2001). Of interest is the ability of TGF-p to induce an
epithelial to mesenchymal transition (EMT) in these cells. EMT is characterized
by the down regulation of proteins involved in cell-cell adhesion and upregulation
of molecules important for cell-extracellular matrix associations, ultimately
leading to enhanced migratory and invasive properties of the cell. A switch from
an epithelial to fibroblastoid phenotype occurs frequently during late stages of
carcinoma progression and correlates with the metastatic potential of tumor cells
(Oft et al., 1998).
E. TGF-p Receptor Mutations in Cancer
Differential contributions of type I and II receptors to the diverse biological
actions of TGF-p have been proposed. Inactivating mutations in TGF-pRII occur
in most human colorectal and gastric carcinomas with microsatellite instability
(MSI) (Markowitz et al., 1995). Stable transfection of wild-type TGF-pRII into a
human MSI colon cancer cell line (Wang et al., 1995) and a human gastric
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cancer cell line (Chang et al., 1997) restored TGF-(3-mediated growth arrest and
reduced tumorigenicity in athymic mice, providing further evidence that
mutational inactivation of TGF-p receptors is a pathogenic event. MSI is common
to many sporadic cancers and results from DNA mismatch repair (MMR) defects
causing nucleotide additions or deletions in simple repeated sequences, or
microsatellites, throughout the genome (Wang et al., 1995). MMR in one such
microsatellite, a 10 bp polyadenine repeat within the TGF-pRII sequence
encoding a part of the extracellular domain (referred to as the BAT-RII track),
results in a frameshift and a truncated, inactive TGF-pRII product (Markowitz et
al., 1995). BAT-RII inactivating mutations are also found in colorectal and gastric
tumors from patients with hereditary nonpolyposis colon cancer (HNPCC), a
familial cancer syndrome in which affected individuals inherit defects in genes
encoding components of the DNA MMR pathway (Lu et al., 1996; Akiyama et al.,
1997). Recently, missense mutations of TGF-pRII, most of which target the
kinase domain, have been reported in 15% of microsatellite stable colon cancers
examined (Grady et al., 1999). Thus, inactivating mutations of TGF-pRII may be
present in as many as one quarter of all cancers (Fig 4). Over expression of a
functional TGF-pRII in prostate cancer causes tumor inhibition by restoring TGFp sensitivity (Guo and Kyprianou, 1998). Figure (4) summarizes the different
mutations hot zones on the TGF-p R2 protein.
Mutational inactivation of the TGF-pRI, has also been detected in human
cancers. An inactivating mutation in TGF-pRI occurs in one third of ovarian
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Fig 4 Block diagram showing mutation
prone regions of the TGF-pR2.
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cancers examined. Interestingly, in the same tumor cohort, no inactivating
mutations were identified in TGF-pRII (Wang et al., 2000). A missense mutation
in the kinase domain of TGF-pRI, resulting in a hypomorphic allele, has been
identified in one cohort of metastatic breast cancers (Chen et a!., 1998) but not in
another (Anbazhagan et al., 1999). In addition, deletions of TGF-pRI occurred at
a low frequency in pancreatic and biliary carcinomas (Goggins et al., 1998) as
well as cutaneous T cell lymphoma (Schiemann et al., 1999).
F. Smad Mutations in Cancer
The TGF-p signaling network is also disrupted in cancer by mutations in
Smad4 and Smad2. Smad4, initially identified as deleted in pancreatic carcinoma
locus 4 (DPC4) located on 18q21, suffers biallelic loss in half of all of pancreatic
cancers (Hahn et al., 1996), one-third of metastatic colon tumors (Miyaki et al.,
1999), and smaller subsets of other carcinomas. Occasionally, Smad4 mutations
have been found in conjunction with TGF-pRI mutations in biliary cancer
(Goggins et al., 1998) and with TGF-pRII mutations in colon cancer (Grady et al.,
1999). Smad4 and the TGF-p receptors may therefore have certain non
overlapping tumor suppressive activities.
Smad2, also located on 18q21, is the target of inactivating mutations in a
proportion of colorectal cancers (Eppert et al., 1996). Inactivation of Smad2 and
Smad4 occurs by loss of the entire chromosome region, small deletions, frame
shift, nonsense mutations, or missense mutations. Missense mutations mostly
target the MH2 domain, resulting in loss of stability or disruption of homo- and
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hetero-oligomerization of the Smads. Among the missense mutations in the MH1
domain, one targeting the same conserved residue in both Smad2 and Smad4
resulted in an enhanced autoinhibitory interaction between the MH1 and MH2
domains and additionally decreases protein stability (Xu and Attisano, 2000).
Smad-deficient mice display phenotypes in support of a tumor suppressor role for
the Smads. Although mice with homozygous loss of Smad2 and Smad4 die in
utero, their heterozygous counterparts are viable. In fact, mice heterozygously
null for Smad4 developed gastric polyps that developed into tumors at a late age
(Xu ef a/., 2000). Furthermore, mice defective in adenomatous polyposis coli
(APC) developed numerous indolent intestinal polyps. When mice with one
mutated APC allele were crossed with heterozygous null Smad4 mice, the
compound heterozygotes developed larger polyps that progressed into malignant
adenocarcinomas with loss of the remaining copies of both APC and Smad4
(Takaku et al., 1998). Moreover, although no Smad3 mutation has been found in
human cancer, mice with a homozygous deletion of Smad3 develop aggressive
metastatic colorectal cancer at an early age in a manner that seems to be highly
dependent on the genetic background of the mice (Zhu et al., 1998).
G. H238
Boyd and Orme (Boyd and Orme, 1975) transformed BALB/c mouse
embryo fibroblasts to malignancy by using ultraviolet-inactivated HSV-2. These
transformed cells, designated H238, expressed viral antigens on the cellular
membrane and tumor antigens in the nucleus. Small H238 tumors
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spontaneously regress in a portion of injected animals, suggesting that the cells
are immunogenic. The advantage of using such an immunogenic tumor model
circumvents the problem of a non-self immune response and provides an ideal
environment to study the cytokine interaction necessary to elicit an anti-tumor
immune response.
We have demonstrated and confirmed the ability of H238 cells to produce
transforming growth factor (TGF-(31), a down regulator of the host’s immune
capacity to eliminate neoplastic cells. In addition, Stagg R (1988) identified four
potential factors expressed by the H238 fibrosarcoma in his dissertation study.
These were tentatively identified as PDGF, FGF, TGF-(3 and an un-identified
splenocytes proliferation inhibitor. Das et al, (1991) confirmed the inhibitor to be
TGF-p. Our studies have established this animal cell line as an effective animal
model to investigate the role of HSV-2 in tumor production and to study cytokine
modulation byTGF-pi (Das et al., 1991;Gridley eta!., 1993; Mao etal., 1994;
Mao et al., 1995). In addition, the syngeneic nature of this tumor provides an
ideal model to study the interaction of tumor expressed TGF-p on the immune
system without the interfering aspects on a non-self immune response.
FI. Antisense Gene Therapy
The concept of antisense-mediated gene inhibition, first introduced by
Stephenson and Zamecnik in 1978, has now emerged as a potentially powerful
alternative or adjunct to conventional cancer chemotherapy (Flelene, 1994). The
discovery that synthetic fragments of DNA can inhibit the transcription and/or
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translation of selected genes in a sequence-specific manner initially opened up a
new mechanism for analyzing gene function, then launched a new field of drug
development in which early clinical trials are now proceeding (Crooke and
Bennett, 1996).
Clinical applications for antisense therapy has been envisioned in many
fields including oncology, vascular and genetic diseases, and the treatment of the
human immunodeficiency virus (Rossi, 2000 and Michienzi et al, 2000) and other
viral infections (Calabretta, 1991). The term "antisense" refers to the fact that the
nucleic acid, either DNA or RNA, synthesized is complementary to the coding
(i.e., "sense") genetic sequence of the target gene (Brysch and Schlingensiepen,
1994). Antisense constructs hybridize in an antiparallel orientation to nascent
mRNA through Watson-Crick base-pairing. Theoretically, an oligomer 17
nucleotides in length should find a unique target within the 3 x 109 base pairs of
the human genome (Helene, 1994).
To date, two main antisense strategies have been employed: transfection
of cells with antisense cDNA and treatment of cells with the shorter antisense
oligodeoxynucleotides (ODNs). The former strategy has been successfully used
in vitro against gene targets such as basic fibroblast growth factor (bFGF)
(Redekop and Naus, 1995), protein kinase C isotype a (Ahmad et al., 1994),
TGF-p (Dorigo et al., 1998) and in animal models targeting insulin-like growth
factor 1 (Shevelev et al., 1997) vascular endothelial growth factor (Cheng et al.,
1996) or the immunosuppressive IL-10 (Kim et al., 2000)
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A number of studies have utilized antisense TGF-p strategies or antibody
neutralization approaches to evaluate the effect of reduced TGF-p production on
tumor growth and immune responses (Fakhrai et al., 1996, Dorigo et al., 1998,
Park et al., 1997, Arteaga et al., 1993). Such modalities clearly enhance anti
tumor natural killer cell and cytotoxic T lymphocyte responses.
Suppression of TGF-p production by tumors has resulted in delayed tumor
growth or outright tumor rejection in a variety of tumor models. Using a zincinducible antisense TGF-p construct, Marzo et al (1997) demonstrated that
inhibition of TGF-p secretion resulted in decreased tumor growth and mortality of
mice injected with malignant mesothilium cells. This inhibition of tumor growth
was attributed primarily to diminished production of TGF-p, which normally
stimulates the growth of these cells. In addition, the decreased expression of this
cytokine may have contributed to an elevated anti-tumor immune response.
Using a rat glioma model, Fakhrai et a/(1996), showed that immunization of with
antisense transfected 9L cells eradicated 5-day established intracranial gliomas.
Lymph node cells isolated from these animals demonstrated enhanced in vitro
cytotoxic activity. These findings in different tumor models underscore the
probable universality of TGF-p-mediated tumor escape and demonstrate that
reduction of TGF-p secretion by tumor cells can result in restoration of immune
function that may contribute to elimination of the disease in vivo. In most of these
studies, however, reduction of TGF-p secretion failed to destroy the tumors
completely.
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Because immune escape mechanisms are multi-faceted, it is not
surprising that reduction in immune suppression alone may be inadequate to
cause complete tumor regression in all cases. It is for this reason that current
studies utilize a two-pronged attack; an antisense modality used concurrently
with an immunostimulatory approach using, cytokines such IFN-y, IL-12 or IL-2.

I. IL-2
First characterized biochemically from Jurkat cells, a human T cell
leukemic line, human IL-2 is a glycoprotein with an apparent molecular weight of
15,000 - 18,000, (Taniguchi etai, 1983). Natural IL-2 is glycosylated and varying
degrees of glycosylation apparently account for the observed range of molecular
weights seen on SDS-PAGE. Human IL-2 is synthesized as a polypeptide of 153
amino acid residues. Murine IL-2 is approximately 63% identical to human IL-2,
but contains a unique stretch of repeated glutamine residues (Kashima et al.,
1987). There is marked species cross-reactivity, as human IL-2 has been found
to be active on murine cell lines. The three dimensional structure of human IL-2
has been determined using X-ray crystallography, and this has shown IL-2 to be
an alpha-helical protein with a four-fold core and no beta-sheet structure (Bazan,
1992) (Fig. 5). Cells known to produce IL-2 include thymocytes (Xin et al., 1994),
gamma delta T-cells (Tsukaguchi et al., 1995), B-cells (Bovia et al., 1998) and
CD4+ and CD8+ T-cells (Conlon et al., 1995). The biological activities of IL-2 are
mediated through the binding of IL-2 to a multisubunit cellular receptor (IL-2R).
Cells known to express alpha-chains include activated and resting CD4+ and
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Fig. 5 Three dimensional structure of
human IL-2
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CD8+ T cells (Minami and Taniguchi, 1995), resting and activated B cells
(Nakanishi et al., 1992), embryonic fibroblasts (Plaisance ef a/., 1992),
glioblastoma cells (Benveniste et al., 1988), activated monocytes (EspinozaDelgado etal., 1995), and various tumor cells (Weidmann et al., 1992). The
second subunit to be isolated was the beta subunit, a 70 kDa, 525 aa residue
glycoprotein that possesses an extensive 286 aa cytoplasmic region (Fujii et al.,
1998). Cells known to express the beta-chain include activated CD56+ (NK) cells
plus CD8+ and CD4+ T cells, resting NK cells and, perhaps, CD8+ T cells
(Vanham et al., 1994), activated and resting B cells (Nakanishi et al., 1992),
embryonic fibroblasts (Plaisance etal., 1992), resting monocytes (EspinozaDelgado et al., 1995) and neutrophils (Djeu et al., 1993). The last subunit to be
discovered was the gamma chain. This is a 64 kDa, 347 aa residue glycoprotein
that contains an 86 aa cytoplasmic region. Although no obvious catalytic motif
has been identified in this cytoplasmic domain, ligand internalization seems to be
dependent upon the gamma-chain (Takeshita et al., 1992). Thus, it is suggested
that the beta and gamma-chains may interact through their cytoplasmic domains
to transduce an IL-2 signal (Minami and Taniguchi, 1995) (Fig. 6). Soluble forms
of many cytokine receptors have been reported in recent years, and a soluble
form of IL-2 alpha-receptor appears in serum, concomitant with its increased
expression on cells (Honda et al., 1990).
IL-2 is a lymphokine synthesized and secreted primarily by T helper
lymphocytes that have been activated by stimulation with certain mitogens or by
interaction of the T cell receptor complex with antigen/major histocompatibility
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Fig. 6 Three dimenesionai structure of ILreceptors (Honda et al, 1990)
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complex (MHC) on the surfaces of antigen-presenting cells (Morgan et al., 1976).
The response of T helper cells to activation is induction of the auto expression of
IL-2 and receptors for IL-2 and, subsequently, clonal expansion of antigenspecific T cells. At this level IL-2 is an autocrine factor, driving the expansion of
the antigen-specific cells. IL-2 also acts as a paracrine factor, influencing the
activity of other cells, both within the immune system and outside of it. B cells
(Waldmann etal., 1984) and natural killer (NK) cells (Spagnoli et al., 1993)
respond, when properly activated, to IL-2. The lymphocyte activated killer (LAK)
cells (Lotze et al., 1981), appear to be derived from NK cells under the influence
of IL-2. Other cells under the possible influence of IL-2 are neutrophils (Djeu et
al., 1993), monocytes (Espinoza-Delgado et al., 1995), and gamma delta T cells
(Nistico and De Sarro, 1991), all of which demonstrate either activation,
augmented function, or increased survival when exposed to IL-2.
Because of the central role of the IL-2/IL-2R system in mediation of the
immune response, it is obvious that monitoring and manipulation of this system
has important diagnostic and therapeutic implications. IL-2 has shown promise
as an anti-cancer drug by virtue of its ability to stimulate the proliferation and
activities of tumor-attacking LAK and TIL (tumor-infiltrating lymphocytes) cells
(Yang et al., 1991). The monitoring of increased serum levels of IL-2 and soluble
IL-2 receptor, shows promise as a predictor of the onset of rejection episodes in
allograft recipients (Kirkman et al., 1985). Antibodies against IL-2 or IL-2
receptors may have potential in the prevention of allograft rejection and
suppression of autoimmune diseases (Kelley et al., 1988). However, toxicity
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issues with the systemic delivery of IL-2 are still of concern and require
considerable investigation (Rubin, 1993).
To circumvent the difficulties of systemic and intra-tumoral cytokine
administration, several groups have explored gene transfer as an alternative
method of cytokine delivery. Immunogene therapy is the most pursued form of
gene therapy in current clinical trials. Most of these studies involve the
administration of tumor cells vaccines genetically modified ex wVo to express
cytokine genes. Additional ex vivo immunogene therapy approaches include
cytokine gene modification of Til’s or antisense inhibition of differentiation and
immunosuppressive factors. This approach is designed to provide the benefit of
local cytokine administration at the site of antigen priming and would obviate the
need for multiple intralesional injections. The concentration of cytokines secreted
by tumor cells is sufficient to induce anti-tumor immunity but too low to produce
systemic cytotoxicity. In addition, the continuous expression of functional
cytokines may also produce greater augmentation of anti-tumor immune
response compared to that of intermittent cytokine injections.
Cytokine gene transfer has resulted in significant anti-tumor immune
responses in several animal tumor models. In these studies, the transfer of
cytokine genes into tumor cells has reduced or abrogated the tumorigenicity of
the cells after implantation into syngeneic hosts. The transfer of cytokine genes
for IL-2 (Iwadate et ai, 2000), IFN-y (Knupfer et al., 2000) and IL-12
(Rakhmilevich et al., 2000) significantly reduced or eliminated the growth of
several different histological types of murine tumors. In studies employing IL-2
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gene transfer, treated animals developed systemic anti-tumor immunity and were
protected against subsequent tumor challenges with unmodified parental tumor
cells. Similar inhibition of tumor growth and protective immunity were also
demonstrated when immunizations were performed with a mixture of unmodified
and genetically modified tumor cells engineered to express the IL-2 gene
(Zitvogel et a!., 1995). Surprisingly, no toxicity associated with the expression of
these cytokine transgenes was reported in these animal tumor studies.
In studies employing a murine colon tumor model, immunizations with a
mixture of irradiated tumor cells and IL-2 transduced fibroblasts generated
systemic anti-tumor immunity capable of rejecting subsequent tumor challenge
and eradicating established tumors (Shawler ef a/., 1995). Tahara and co
workers observed similar results in a murine melanoma model following
immunizations with tumor cells and allogenic fibroblasts genetically modified to
express IL-2 (1995). In related animal studies, Sun and associates (1995)
induced systemic anti-tumor immunity following immunizations with IL-2 secreting
fibroblasts that were also transfected with tumor DNA. These results support the
development of tumor vaccines containing autologous or allogeneic fibroblasts
genetically modified to secrete cytokines as a means of enhancing anti-tumor
immune responses.
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PREVIOUS WORK DONE
Our laboratories have been studying the murine immune response to the
H238 tumor cell for several years. An initial study (Nutter et al., 1980) described
the responses of mouse spleen morphology to the growth of these tumor cells.
This study documented that differential counts of spleen cells resulted in
increases in the proportion of mature granulocytes and immature cells with a
proportional decrease in the lymphoid cell population in mice with progressive
tumors.
Diet and carcinogenesis was also studied using this system (Gridley et al.,
1982; 1987). These studies showed an enhanced immunological capacity with
tumor-reducing diets compared to mice fed a high-fat wheat protein diet,
demonstrating that H238 tumor progression could be modified by dietary
manipulation. A decline in immune status with progressive H238 tumor growth
mediated by a suppresser macrophage population was also reported (Hyde et
al., 1985). Based on these observations, we have utilized this system to
evaluate tumor progression with various treatment modalities and to determine
how these tumors escape the hosts’ immune system.
A significant finding reported that the conditioned medium (CM) from H238
cell cultures was able to decrease mitogen-induced lymphoblastogenesis of
mouse host spleen cells and enhance the oxidative burst from total and adherent
spleen cells from normal mice (Das et al., 1991). This report demonstrated that
H238 tumors could alter lymphocyte and phagocytic functions both in vivo and in
vitro, most likely via secretion of soluble factors. Das, et al (1991) characterized
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the modifying factor present in the H238 CM via Northern blot analysis and
chromium release assays, and ascertained that H238 cells produced and
secreted TGF-p. Antibody to TGF-p completely blocked the suppressive activity
in spleen cell lymphoblastosis and suggested that TGF-p acted as the main
inhibitor of immune responses found in the FISV-2 induced murine tumor cell line.
An additional study tested whether polyclonal anti-TGF-p antibody and
recombinant IL-2 (Gridley etal., 1993) could inhibit H238 tumor progression in
vivo when administered alone and/or in combination. They demonstrated that IL2, and to a lesser extent IL-4, was able to counteract the suppressive effect of
TGF-p in vitro on mitogen-stimulated spleen cells. This study also documented a
3-4 fold decrease in IL-2 production in normal spleen cells, giving rise to a
possible target of TGF-p immunosuppression. Gridley et a/(1993) showed that
IL-2 and anti-TGF-p could be safely administered intra-peritoneally, but found
enhanced tumor formation in the mice treated with IL-2 alone and with the
antibody to TGF-p. The next step was to study modifications in dosages,
schedule, or route of injection to see if these factors could influence H238 tumor
development and immune activation.
Two studies (Mao et al., 1994; 1995) showed that low-dose IL-2 alone and
in combination with anti-TGF-p antibody or interferon (IFN-y) could successfully
retard progression of the H238 tumors. Interestingly, single treatment modalities
appeared to be more effective than combination therapies.
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The advent of non-viral gene therapy techniques thus presented a novel
strategy to attack cancer. The effectiveness and elegance of genetic engineering
techniques is derived from low toxicity, targeted administration, induction of long
lasting immunity, stability and the ability to activate cytotoxic T cells unlike
conventional vaccines. With these principles in mind, this project attempted to
use antisense TGF-p and IL-2 immunostimulatory cytokine gene therapy to
attempt to enhance the host’s immune system against the aggressive H238
tumor.
The hypothesis underlying this proposal is that TGF-p producing H238
tumor cells expressing lower levels of TGF-p or tumor cells producing IL-2 would
combine to boost the host’s suppressed immune capacity to limit H238 tumor
formation. Specifically, this project attempted to determine any effect of murine
antisense TGF-p and murine sense IL2 transformed H238 cells on tumor
development in an immunocompetent BALB/c mouse. In addition, the presence
of functional TGF-p receptors on H238 cells was investigated. This assessment
may explain, in part, why TGF-p lacks an effect on H238 cell proliferation.
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MATERIALS & METHODS
A. Media
H238, C6, CV1 and CCL-64 cells were maintained in Dulbecco’s minimal
essential medium (DMEM; Irvine Scientific, Santa Anna, CA) supplemented with
5% bovine calf serum (BCS; Hyclone Laboratories, Logan, UT), 100pg/ml
fungizone (Sigma Chemical Co., St. Louis, MO) and 50pg/ml gentamycin (Sigma
Chemical Co., St. Louis, MO). This will be referred to as complete DMEM media.
Luria-Berani (LB) broth was prepared from the protocol outlined in
Sambrook J et al., (1989). Per liter: 10g NaCI, 10g bacto-tryptone, 5g bacto-yeast
extract was added and autoclaved for 20 min. For LB agar plates, 15g of bactoagar was also added prior to autoclaving.
Transformation recovery media used was SOC, which was prepared per
liter as follows: 20g-bacto-tryptone, 5g-bacto-yeast extract, 0.5-sodium chloride.
This was autoclaved for 20 min, cooled to 50°C and 20ml of sterile 1M glucose
added.
B. H238, C6, CV1 and CCL-64 culture conditions
The H238 tumor cell line is a murine fibroblast cell line originally derived
from cells transformed in vitro with UV-inactivated Herpes simplex virus type-2
(Savage strain) (Boyd and Orme, 1975). They were maintained as monolayers in
complete DMEM. At 70% confluency, the cells were split 1:3. The monolayer was
washed with 2-5ml of Hanks Balanced Buffered Salt Solution (HBSS) (Sigma
Chemical Co., St. Louis, MO) and trypsinized with 1X trypsin (Difco Laboratories,
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Detroit, Ml). To dislodge the cells, the flask was tapped sharply several times
with the palm of the hand. The trypsin was neutralized by pipetting the
trypsin/H238 cells suspension into 5-8ml of complete DMEM with 5% BCS. Stock
H238 cells were stored frozen in liquid nitrogen in freeze media (10% DMSO +
10% BCS-containing DMEM).
Rat C6 glioma cells (American Tissue Culture Collection, CCL-107) were
grown in complete DMEM. The cells were maintained at 37°C/5% C02 and sub
cultured once at 70% confluency. The C6 cells were sub-cultured according to
the same procedure used for the H238 cells as outlined above.
C. Plasmid Vector Construction
All vectors used in this project were constructed from pcDNA 3.1 (pc3;
Invitrogen, Carlsbad, CA) (Fig. 15). This vector provided several unique features,
which made it very appropriate: 1) Strong constitutive cytomegalovirus (CMV)
promoter, 2) SV40 origin of replication and the neomycin selection marker,
allowing stable clone selection and 3) an ampicillin selection marker for E. coli
selection. All the restriction enzymes used for this study were obtained from New
England Biolabs (Beverly, MA). The basic protocols for restriction digestion and
ligation reactions were obtained from Sambrook et al (1989).
1. Cloning of antisense TGF-(31
The antisense TGF-p probe (pmTGF-p1a) was obtained from Dr. H.
Moses (Vanderbilt Cancer Center, Nashville, TN). The probe was excised from
the parental vector (pmTGFpla) using Smal restriction digest for 5 hrs at room
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temperature (25°C) using the NEBuffer4 (50 mM potassium acetate, 20 mM
Tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol (pH 7.9 @ 25°C).
One microgram of the probe was used for the digestion reaction. The digested
probe was purified using gel electrophoresis using an agarose DMA purification
kit (QIAEX II; Qiagen). The protocol for this procedure was followed directly from
the Qiagen handbook. Further details on this can be found at:
http://www.qiaqen.com/literature/handbooks/qexll/qiaexll agarose.pdf
Briefly, the DMA band was excised from the agarose gel with a clean, sharp
scalpel. Excess agarose was removed to minimize the size of the gel, which was
then placed in a 1.5-mL colorless microfuge tube for processing. The gel slice
was weighed in the tube to which Buffer QX1 was added in the ratio of three
volumes buffer to one volume of gel. After QIAEX II was resuspended by
vortexing for 30 seconds, 10pl of QIAEX II was added to the microfuge tube and
the sample was mixed. To solubilize the agarose allowing DMA binding, the
sample was incubated at 50°C for 10 minutes. QIAEX II was kept in suspension
by vortexing every 2 minutes. If the color was orange or purple, 10 pi of 3M
sodium acetate (pH 5.0) was added to maintain an optimal pH for DMA binding
and the contents were re-mixed. The sample was then centrifuged for 30
seconds and the supernatant was carefully removed with a pipet. The pellet was
then washed with 500 pi of Buffer QX1 to remove agarose contaminants and
washed twice with 500 pi of Buffer PE to remove salt contaminants. The pellet
was then air-dried for 10-15 min or until it became white. Overdrying was
avoided to maintain elution efficiency. To elute the DMA, the pellet was
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resuspended in 20 pi of 10 mM Tris-CI (pH 8.5) and incubated at SOX for 5
minutes. The sample was centrifuged for 30 seconds and the supernatant, which
contained the purified DMA, was carefully pipetted into a clean microfuge tube.
The purified product (975bp) was ligated with a purified Smal digested pc3
backbone vector using a proportion of 1:4 for the backbone to insert ratio in a
final volume of 20pl. The ligase used was T4 DMA ligase (100, 000 units); the
reaction was incubated at 16°C overnight in a water-bath (Sigma Chemical Co,
St. Louis, MO). Twenty single bacterial colonies were selected using sterile
technique and propagated individually in 3ml of LB media with Ampicillin. The
sterile technique involves flaming the inoculating loop, prior to handling any
bacterial cultures. The loop should be re-flamed after handling the bacteria.
Instead of using an inoculating loop, sterile toothpicks (autoclaved) can be used.
Plasmid DMA was extracted from these colonies using the mini prep
method described in the following pages and preliminary insert orientation
analyzed using restriction digests. A suitable clone was identified based on the
correct restriction pattern obtained after digestion of the respective plasmid. The
plasmid from the clone was then sequenced using the forward T7 priming site
(5’-TAATACGACTCACTATAGGG-3’) and the reverse BGH priming site (5’TAGAAGGCACAGTCGAGG-3’) to confirm the orientation. The clone
representing the correct plasmid was propagated on a larger scale to maintain
stock cultures using the transformation procedure described below. Plasmid
extraction was done using either the Qiagen plasmid MIDI kit or cesium chloride
purification techniques as described below.
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2. Cloning of murine Interleukin 2
The murine IL-2 cDNA was obtained from the VR1103 plasmid, a kind gift
from Dr S. Parker (Vical Inc.; San Diego, CA). The cDNA was excised using the
Kpn I and Pst I sites and subcloned into the pc3 plasmid in the same sites. Using
the same technique outlined above, single cell colonies were obtained and
analyzed for correct orientation. The final clone selected was sequenced using
the same primers used above. The clone representing the plasmid was
propagated on a larger scale to maintain stock cultures, by the transformation
protocol given below. This was done using either the Qiagen plasmid MIDI kit or
the cesium chloride purification techniques as described below.
D. Transformation and Propagation of E. coli
During the course of this study, the heat shock transformation protocol
was utilized for the propagation of plasmid DNA in E. coli. The competent E. coli
cells used were XL2-Blue MRF’ (Stratagene; La Jolla, CA). These cells were
stored at -80°C at all times, as they are very sensitive to temperature
fluctuations. Prior to aliquoting the cells, the SOC media was pre-heated to 42°C.
The cells were thawed on ice and gently mixed by tapping at the pellet. After
thawing, 1Q0pl of the competent cells were aliquoted into pre-chilled microfuge
tubes. Two microliters of 2mM p-mercaptoethanol (Stratagene; La Jolla, CA) was
added per tube to enhance the efficiency of DNA transformation. The cells were
mixed gently but thoroughly by hand and incubated on ice for 10 min. Generally,
100-500ng of plasmid DNA was used for each transformation reaction and the
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mixture swirled gently. The tubes were incubated on ice for 30 min to equilibrate
the contents and then heat pulsed at 42°C for 30 sec EXACTLY. Nine hundred
microliters of the pre-heated SOC was added to the cells to allow recovery and
the tubes incubated at 37°C for 1 hour. One hundred microliter aliquots of the
cells were plated on to LB agarose plates supplemented with Ampicillin (Sigma,
St. Louis, MO) at 100pg/ml and incubated at 37°C for 12-16hrs. Amp resistant
colonies were picked using sterile toothpicks and propagated in 3ml of LB broth
supplemented with 100pg/ml Ampicillin (Sigma).
E. DNA Extraction

1. Qiagen MIDI DNA extraction
Plasmid DNA was extracted from XL2-Blue cells using the Qiagen QIAfilter
Plasmid Midi Kit. Detailed versions of this protocol can be found at the following
web site:
MIDI Prep: http://www.qiagen.com/literature/handbooks/plk/qfmidmax.pdf
Briefly, exponentially growing XL2-Blue E. coli cells were inoculated 1:500 into
LB broth (25ml final volume) with the addition of the appropriate antibiotic and
incubated overnight at 37°C with constant agitation at 250rpm. The cells were
harvested at 6000g for 15min at 4°C and resuspended in 4ml of P1 buffer (50mM
TrisHCI, 10mM EDTA, 100pg/ml RNase A). The pellet was lysed in 4ml of P2
buffer (200mM NaOH, 1% SDS) and neutralized in 4ml of P3 buffer (3M
potassium acetate, pH 5.5). The cell lysate was poured into the barrel of a
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QIAfilter cartridge and left to incubate at room temperature for 10 min. Passing
the lysate through a column containing a patented Qiagen Anion Exchange
Resin (QIAfilter Plasmid Midi Kit, # 12245), purified the plasmid DNA. The bound
DNA was washed by buffer QC (1M NaCI, 50mM MOPS pH 7.0, 15%
isopropanol) and eluted using buffer QF (1.25mM NaCI, 50mM TrisHCI pH 8.5,
15% isopropanol). Plasmid DNA was precipitated by adding 0.7 vol of
isopropanol and centrifuged at >15,000g for 30min at 4°C in a Sorval RC5
Dupont Centrifuge. The plasmid precipitate was washed with 2ml of 70% ethanol
by centrifugation at 15,000g for 10 min, using the same centrifuge, and allowed
to air dry for 10-30min at room temperature. The plasmid precipitate was
resuspended in 100pl ofTris EDTA buffer (TE; 10mM TrisHCI pH 8.0, 1mM
EDTA pH8.0). DNA was quantified in a Beckman Du-650 (Beckman Instruments
Fullerton, CA) spectrophotometer at A26onm and the purity evaluated with the
A26o/28onm ratio.
Sample Calculation:
DNA dilution 1:20, A26o = 0.5, A26o/28o = 1 -765
DNA cone, (pg/pl) = 0.5 x 20(dil factor) x 50(DNA factor) = 0.5pg/pl
1000 (ml-> pi)
2. Cesium Chloride Extraction for Large DNA Preps
For large preparations of DNA, the cesium chloride technique was utilized.
This technique yielded DNA, which was of high purity and low endotoxin content.
All the P buffers used were identical to those used for the Qiagen Extraction
procedure. An overnight culture of bacterial cells (2 liters) was harvested by
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centrifugation at 7000rpm for 10 min. The cell pellet was resuspended using P1
buffer (20ml/500ml of culture) and lysed in P2 buffer (40ml/500ml of culture) at
room temperature. The lysate was mixed by inversion to ensure complete mixing
and was neutralized using P3 buffer (30ml/500ml of culture) at room temperature
for 5-10min. The lysate was centrifuged at 12000rpm for 1hr at 4°C. Mixing well
with 0.6 volume of ethanol precipitated the supernatant, followed by centrifuging
immediately at 8,000rpm for 20min in a GS3 rotor using the Sorval RC5 Dupont
Centrifuge to collect the plasmid DNA precipitate. The supernatant was
discarded and the DNA pellet dried under a vacuum tap for 10 min. The dried
DNA pellet was resuspended completely in 8ml of TE (pH 8.0). Eight point eight
grams of cesium chloride was added to the DNA solution and dissolved by mixed
thoroughly. Eight hundred microliters of ethidium bromide solution (10mg/ml) was
added and mixed well. Using a 20ml syringe and an 18G needle, the DNA
solution was aspirated into 10ml ultracentrifuge tubes (Beckman; Palo Alto, CA)
until the meniscus reached the nozzle. The tubes were balanced and the
openings heat-sealed. Squeezing the sealed tubes gently confirmed presence of
any leakage. Depending on the size of the tubes, the appropriate centrifuge rotor
was used (5ml - Ti90, 10ml - SW40) and the tubes centrifuged at 65,000rpm for
16 hrs in a Beckman XL-90 Ultracentrifuge. The DNA ‘band’ was removed by
puncturing the tube with a needle as shown below. The DNA was extracted from
the ethidium bromide by washing with an equal volume of butanol six times, and
precipitated using 2 volumes of TE (pH 8.0) and 6 volumes of ethanol. The
volume will depend on the approximate volume that the DNA is recovered from.
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The solution was centrifuged for 20 min at 12,000rpm in a swinging bucket rotor
(Sorval HB4) using the Sorval RC5 Dupont Centrifuge to precipitate the DNA.
The DNA pellet was washed with 10ml of 70% ethanol by hand mixing well and
centrifuging at 20,000rpm for 20 min. The purified DNA pellet was resuspended
in TE and quantified using either the Beckman Du-650 spectrophotometer
(Beckman Instruments) or a fluorometer, depending on the concentration of
DNA.

A/

Needle 1 inserted here

Junk Material
Nicked plasmid DNA
Double Stranded plasmid DNA
Needle 2 inserted here - bevel up

Beckmann ultracentrifuge tube showing plasmid
DNA bands, and insertion points for needles to
facilitate plasmid removal

3. Mini Prep DNA Extractions
This procedure was used to screen large number of colonies during
cloning experiments. The P buffers used were identical to the ones used for MIDI
prep DNA extraction. A bacterial colony was selected, inoculated into 3ml of LB
broth supplemented with the appropriate antibiotic and cultured overnight at 37°C
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with constant agitation. Under sterile conditions, 2 ml of the culture was
centrifuged after 24hrs in an Eppendorf centrifuge 5417C. The bacterial cell
pellet was resuspended in 100pl of R1 buffer and lysed in 250pl of P2 buffer. The
lysate was mixed thoroughly by repeated inversion of the tube, neutralized by
adding 150pl of P3 buffer and incubated on ice for 5 min. The lysate was
centrifuged (14000rpm for 2min in an Eppendorf 5417C centrifuge) to remove
protein and genomic DNA and the supernatant transferred into a clean microfuge
tube. Plasmid DNA in the supernatant was precipitated by the addition of 200pl of
cold ethanol (200 proof) and centrifuged for 5min at 14000rpm. The supernatant
was discarded and the DNA pellet resuspended in 100pl of 70% ethanol and
centrifuged for 1min at 14000rpm to remove excess salt. The DNA pellet was
dried at room temperature for 2-3hrs and resuspended in 40-50pl of TE (pH 8.0)
depending on the size of the DNA pellet. For all restriction reactions using DNA
from this method, 5pl of DNA/reaction were utilized.
F. Quantification of DNA using a Hoefer Mini-Fluorometer
The flourometer was warmed up for an hour. In the meantime, a 10ml
solution of working dye was prepared by mixing the following: 1.0 ml of 10X TNE
pH7.4, 20pl of Hoechst 33258 Stock solution and 9ml of ddH20. This was filtered
through a 0.45p membrane filter. Two ml of the working dye was added to a
cleaned quartz cuvette. Care was taken to avoid touching the bottom of the
cuvette. The cuvette was placed in the fluorometer, and the ZERO knob adjusted
to read 000. The cuvette was maintained in this position for all further readings.
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Working quickly, the cuvette was removed and 4fil of 100^g/ml of standard calf
thymus DNA was added directly to the solution already in the cuvette. The
cuvette was capped with parafilm and mixed by inversion. The cuvette was re
inserted into the fluorometer and the SCALE knob adjusted to 100. The cuvette
was removed, the solution drained and the cuvette rinsed with filtered water. The
cuvette needs to be drained well for the following steps. Two ml of the working
dye solution was added to the cuvette, followed by 4pl of the unknown DNA. The
cuvette was mixed by inversion as before, and inserted into the fluorometer. The
reading should be between 1-100. If not, less DNA was used. The readout is not
always stabilized, so the first stable pause was taken to be the correct readout.
The reading obtained was multiplied by 4 to obtain the concentration of DNA in
pg/ml.
G. Transfection Techniques

1. Superfect® Transfection
Wild type H238 were plated at 1 x 105 cells/ml into 60mm dishes (Becton
Dickinson; Franklin Lakes, NJ), 24 hours prior to the transfection to allow
exponential growth. Five micrograms of the plasmid to be transfected was diluted
to a final volume of 150pl using serum-free DMEM media and incubated at room
temperature for 10min. The medium was removed from the cell culture plates
and the cells washed with phosphate buffered saline (PBS). One ml of complete
DMEM was added to the DNA/Superfect (Qiagen; Carlsbad, CA) mixture and
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mixed thouroughly. This mixture was added dropwise very slowly over the cells,
ensuring that it was spread evenly across the cell monolayer. The plates were
incubated at 37°C for 3hrs. The media was aspirated from the wells and replaced
with fresh complete DMEM. For protein expression studies, the conditioned
media was removed every 24hrs, centrifuged and stored at -20°C. To generate
stable transfected cell clones, the cells were allowed to incubate for48hrs post
transfection at 37°C and cloned using the soft agarose method (described below)
with complete DMEM media supplemented with 900|ag/ml of G418 (Calbiochem,
La Jolla, CA). The obtained clones were maintained in complete DMEM media
with 500pg/ml of G418.
2. Calcium Phosphate Transfection - Promega®
Five hundred thousand H238 cells were plated 24 hrs prior to performing
the transfection. Before this procedure was started, all reagents (ProFection®
Mammalian Transfection System, Calcium Phosphate, Promega, Madison, Wl)
were brought to room temperature. The following reagents were combined in
order in a clean microfuge tube (Tube 1), 9pg of DNA and 37pl of CaCI2. The
total volume of the mixture was brought up to 300pl with sterile water. In another
microfuge tube (Tube 2), 300pl of 2X HBSS (Sigma) was added and mixed
thoroughly by vortexing. The DNA/CaCI2 mixture from tube 1 was added
dropwise into tube 2 and incubated at room temperature for 30min. All the
medium from the cell culture wells was removed and the cells washed with PBS.
The combined mixture from tubes 1 and 2 was added dropwise, covering all
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areas of well bottom. The cells were incubated at 37°C for 1 hr followed by the
addition of 1ml of complete DMEM media. After 10hrs at 37°C, 5ml of complete
media was added to the wells. For protein expression studies, the conditioned
media was removed every 24hrs, centrifuged and stored at -20°C. To generate
stable transfected cell clones, the cells were allowed to incubate for 48hrs post
transfection at 37°C and cloned using the soft agarose method (described below)
with complete DMEM media supplemented with QOOpg/ml of G418 (Calbiochem,
La Jolla, CA). The obtained clones were maintained in complete DMEM media
with 500pg/ml of G418.
The plasmids: pc3, pcmasTGFpi and pcmlL-2, were transfected into
H238 cells using this procedure to create either control transfected (pcH238),
antisense transfected (masFI238) and murine IL-2 transfected (H238-IL2) H238
cells.
FI. Luciferase Assay
The firefly luciferase gene was used as our reporter gene of choice, due to
its efficient expression in eukaryotic systems. In addition, the assay (Luciferase
Assay System; Promega, Madison, Wl) to detect expression of this protein
provides adequate accuracy and sensitivity. A detailed protocol for this assay can
be found at:
http://www.promeqa.com/tbs/TB281/tb281.pdf
In summary, the 5X lysis buffer was freshly diluted to 1X prior to use with
d.d. H20. Media from luciferase expressing cells was removed carefully and the
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cells rinsed with PBS thoroughly. Sufficient 1X luciferase lysis buffer was added
to cover the dish (e.g., 400|jl/60mm culture dish (Becton Dickinson; Franklin
Lakes, NJ), QOOgl/IOOmm culture dish (Becton Dickinso; Franklin Lakes, NJ) or
20pl per well of a 96 well plate (Becton Dickinson; Franklin Lakes, NJ). A single
freeze-thaw cycle was included to ensure complete cell lysis. The cell culture
dish was rocked gently to ensure compete coverage of the cells with the buffer.
Using a sterile plastic policeman (Falcon, Lincoln Park, NJ), the cells were
scrapped from the dish, transferred into a microcentrifuge tube and placed on
ice. The cell lysate was vortexed for 10-15 seconds, then centrifuged at 12,000g
for 15 seconds (at room temperature) or up to 2 min (at 4°C). The supernatant
can be transferred into a new tube and stored at -70°C, if long term storage is
required.
The luminometer, was programmed for the appropriate delay and
measurement times. The cell lysate was aliquoted at 20pl/well in an opaque 96
well plate (Dynex Technologies Inc., Chantilly, VA). The luciferase assay reagent
was added to each well (100pl) and the well was read immediately. The light
emission was measured for a period of 10 seconds.
I. Soft Agarose Cell Cloning
This technique provides an ideal method to study the clonogenic
expression analysis of various transfected cells. Prior to starting this assay, 50ml
of a 1.2% (1.2g + 98.8ml of ddH20) and 60ml of a 0.6% (0.6g + 99.4 ddH20)
agarose (Bacto-Agar, Detroit, Ml) solution was prepared. DME (2X) was
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prepared by dissolving 9.936g Dulbelco powder (Mediatech Inc., Herndon, VA),
3.7g of NaHC03 in 500ml of ddH20. Two hundred and fifty mis of the 2X DME
media was diluted with 250ml of ddH20 in a separate bottle. All the prepared
agarose and medium solutions were autoclaved for 20-30 min and equilibrated at
37°C except the agarose/DME which was placed in a 45°C water-bath. Fifty ml of
BCS (HyClone Laboratories, Logan, UT) serum was thawed at 37°C. The base
agarose (BA) layer was prepared by mixing 50ml of 1.2% agarose, 40ml of 2X
DME and 10ml BCS serum. Four ml of BA was pipetted carefully into 12 well
plates (Falcon, Franklin Lakes, NJ). The BA was left to solidify for 15 min at room
temperature and placed in a 37°C incubator. The top agar (TA) was prepared as
follows: 60ml of 0.6% agarose, 50ml of 2X DME and 10ml of serum. Wild type
H238/transfected H238 cells were diluted to a concentration of approximately
100 or 10cells/100pl, which is approximately 1000 or 100 cells/ml. One hundred
microlitres of cells from each dilution was mixed with 2ml of TA and this was
carefully added on top of the BA in each well. The TA was allowed to harden at
room temperature for 15 min and then returned into the 37°C incubator. The
plates were incubated for 2-3 weeks depending on the growth of the cells, with
regular monitoring for contamination and colony growth. Clones of H238 or
engineered H238 cells were identified as a cluster of “grapes” in a spherical
arrangement, growing at an approximate mid-point of the well.
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J. CellTiter 96® AQueous One Solution Cell Proliferation Assay System
This assay is based on a tetra-zolium compound (3-(4,5-dimethylthiazol 2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-fophenyl)-2H-tetrazolium, inner salt;
MTS) and an electron coupling reagent (phenazine ethosulfate; RES) reagent.
MTS tetrazolium compound is bioreduced by cells into a colored formazan
product that is soluble in tissue culture medium, by active respiration of the cells
(by nicotinamide adenine dinucleotide phosphate (NADPH) or nicotinamide
adenine dinucleotide (NADH)). The intensity of the changed color is directly
proportional to the number of viable cells present. For all cells assayed based on
this assay, a standard curve was generated to provide quantitative data for each
cell line. A detailed protocol can be found at:
http://www.promeqa.com/tbs/tb245/tb245.pdf
1. Standard Curve
Cells to be assayed were diluted to 3.84 x 105 cells/1 OOpI or 3.84 x 106
cell/ml. One hundred microliters of this dilution was added to the first four wells
of row A. One hundred microliters of complete DMEM was added to the other
well of column 1. The cells in row A were serially diluted 1:2 down column 1 until
row G to give a range of cell from 3.84 x 105 cells/1 OOpI to a minimum of 3 x 103
cell/1 OOpl. Row H was left empty to serve as the blank control for the media (Fig.
7). 100pl of media was added to all the wells to give a final volume of 200pl.
Previous experience in this assay showed that this addition prevented
evaporation of the media. The 96-well plate was incubated at 37°C for 6hrs so
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Fig. 7 MTS Assay Sandard Plates. The cells in row
A were serially diluted 1:2 down column 1 until row
G to give a range of cell from 3.84 x 105 cells/100^1
to 3000 cell/1 OO^il. Row H was left empty to serve as
the blank control for the media. 100pl of media was
then added to all the wells to give a final volume of
200|liI.
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that the cells could attach to the bottom of the wells. This was verified by viewing
the cells under an inverted microscope (American Optical, Buffalo, NY). At the
same time an aliquot of the MTS reagent was thawed in the dark at 37°C. One
hundred microlitres of media was removed carefully from the wells using a
multichannel pipettor without disturbing the attached cells. Using a repeater
pipettor, 20pl of the MTS reagent was added into each well and the plate
returned into the 37°C incubator. The template was set up on the Benchmark
Microplate Manager Version 5.0 Build 45 (Biorad, Hercules, CA) making sure to
include the negative controls. The plate was read every hour for 4hrs at 490nm
using a Benchmark Microplate Reader (Biorad, Hercules, CA). This provided the
ideal time to read the experimental plates without loss of signal.
2. Experimental Assay
The experimental assay was set-up using the same set up as described
above for the standard curve. However, strip-well plates (Costar, Corning, NY)
were used. Briefly, cells to be assayed were diluted to 5000cells/100pl/well and
added to each well. One hundred microliters of media was added to bring the
final volume to 200pl to compensate for evaporation as before, and the plate
incubated at 37°C. Every 24hrs, the assay strips were removed from the original
plate and placed into a holder. One hundred microliters of media was removed
from each well using a multichannel pipettor, and 20pl of MTS reagent added.
The strips were returned to the incubator, and incubated for the ideal number of
hours determined from the standard curve, (2 hrs). This allowed optimum
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oxidation of the MTS reagent by the cells. The strips were then read at 490nm
using the Benchmark Microplate Spectrophotometer (Biorad).
K. Growth modulation of H238 cells by murine IL-2
Lyophylized murine IL-2 (R & D Systems, Minneapolis, MN) was prepared
to have a final concentration of Ipg/ml. Five micrograms was diluted in 5pl of
ddH20 (1fig/jJ) and 1pl of this concentration was further diluted in 1ml of
complete DMEM (1pg/ml). One hundred microliters of the final dilution was
added to the first 4 wells (100ng/ml or 0.1pg/ml) of row A. Fifty microliters of
normal 5% DMEM media was added to the rest of the wells and using a multi
pipettor, the IL-2 was serially diluted 1:2 with row A/column 1 being the most
concentrated and row H/column 12 being the least concentrated (Fig. 8A). H238
cells were trypsinized, counted in a hemocytometer and resuspended at a final
concentration of 1 x 105 cells/50pl/well (2 x 106 cells/ml). Each plate represented
a 24hr time point with 4 plates being prepared. The plates were incubated at
37°C in a humidified incubator. Another plate of FI238 cells was prepared to
generate a standard curve (Fig. 8B) as described earlier. The growth kinetics in
response to IL-2 was evaluated every 24 hrs with the MTS assay as described
earlier.
L. Radiation Specifications and Procedures
H238 cells were irradiated using y-rays from a cobalt (60Co) source and an
Eldorado Model ‘G’ gamma radiation machine (Atomic Energy of Canada Ltd.,
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Fig. 8 Standard curves and experimental template
to measure the effect of murine IL-2 on H23
proliferation.
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Commercial Products Division, Ottawa, Canada) with the vertical beam projected
to a 20 x 20cm field size. This instrument is located in the Animal Care Facility in
the Loma Linda Medical Center. Doses of 5, 10, 15 and 20 gray (Gy) were
administered to H238 cells at a dose rate of 162.74/min and to achieve full
electronic equilibrium, a 0.5cm bolus (‘Superflab’) was placed on the top of the
dishes. Calibration of the dose was performed with a Capintec Model PR06-G
cylindrical thimble ionization chamber (Capintec, Ramsey, NJ) according to the
National Institute of Standards and Technology (NIST).
H238, pcH238 and H238-IL-2 were diluted to 5 x 104 cells/ml and 100 pis
of this dilution was plated in each well of a 96-well strip well plate (Costar). The
cells were allowed to attach to the well surface for 6 hrs, and then, irradiated at
5Gy, 10Gy, 15Gy, or 20Gy, according to the setup described above. Cell
proliferation was measured every 24hrs using either the MTS or 3H-TDR uptake
as described earlier.
M. In vitro expression analysis of IL-2 and TGF-p
H238, pcFI238, masH238 and H238-II2 cells were plated each in trilplicate
at a concentration of 5 x 105 cell/ml in 6-well plates (Becton Dickenson; Franklin
Lakes, NJ). During trypsinzation of the cells, the media used was a modified
version of complete DMEM prepared with 5% BCS. Additional media (2ml) was
added to the wells to bring the final volume to 3ml/well and the cells incubated in
a humidified 37°C incubator. Media was removed from the wells every 24hrs and
centrifuged at 3000rpm in a swinging bucket centrifuge to remove cellular debris.
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Three ml of the modified DMEM was added in to the wells and the plates
returned for further incubation. Media collection was continued until 100%
confluency was observed. The media was assayed using an Enzyme Linked
Immunoabsorbant Assay (ELISA, R & D Systems, Minneapolis, MN) to quantify
protein.
N. Enzyme Linked Immunoabsorbant Assay (ELISA)
This assay employs the quantitative sandwich enzyme immunoassay
technique. TGF-p soluble receptor Type II or an affinity purified polyclonal
antibody for murine IL2 had been pre-coated onto a microplate, thus any specific
protein present was bound by the immobilized receptor. Two stringent washes
removed any unbound material and a horseradish peroxidase-linked polyclonal
antibody was added to sandwich the TGF-p1 or IL-2 immobilized during the first
incubation. Following a wash to remove unbound antibody-enzyme conjugate, a
substrate solution consisting of 2 parts, a) stabilized hydrogen peroxide and b)
stabilized chromogen (tetramethylbenzidine) was added to the wells and color
developed in proportion to the amount of TGF-pi or IL-2 bound in the first step.
The color development was stopped and the intensity of the color measured
using a Benchmark Microplate Spectrophotometer (Biorad) set at 450nm with
wavelength correction set at 540/570nm. A detailed protocol of the ELISA
procedure forTGF-p1 and IL-2 can be found at:
TGF-pi ELISA: http://www.rndsvstems.com/pdf/DB100.pdf
Murine IL-2 ELISA: http://www.rndsvstems.com/pdf/M2000.pdf
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1. TGF-p Sample Preparation
Latent TGF-p has to be converted to an immuno-reactive form prior to
assaying using the ELISA method. TGF-p present in cell culture supernatant was
activated by the addition of 100pl of 1N HCI (Fisher) (91.67ml ddFLO + 8.33ml of
12N HCI) to 0.5ml of cell culture supernatant. This was incubated at room
temperature for 10 min and neutralized by the addition of 100pl of 1.2N
NaOH/0.5M HEPES (75ml of ddH20 + 12ml of 12N NaOH, mix well and add
11.9g HEPES). Two hundred microliters of the activated sample was assayed.
To compensate for dilution by the activation process, the concentrations obtained
from the standard curve were multiplied by 1.4.
2. TGF-p and IL-2 Standard Preparation
The provided standards were reconstituted using the appropriate
calibrator diluent. This reconstitution made a stock solution of 2000pg/ml of TGFp1 or 1000pg/ml of IL-2. Six 2ml microfuge tubes were set up and 500pl of the
respective calibrator diluent was added to each tube. A 1:2 serial dilution was
carried out using 500pl from the stock, to generate a range of 2000pg/ml 31.2pg/ml of TGF-pi and 1000pg/ml - 15.6pg/ml of IL-2. Prior to constituting
each dilution, the tubes were mixed thoroughly.
O. RNA Extraction
Transfected or wild type H238 cells were propagated in a 100mm tissue
culture treated dish (Falcon/Becton Dickinson; Franklin Lakes, NJ) until
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approximately 75-85% confluency. The cells were washed twice with cold PBS
solution, and 1ml of TRIzol Reagent (Life Technologies Inc., Rockville, MD) was
added slowly dropwise over the cells, ensuring an even spread. Using a sterile
cell scrapper (Falcon/Becton Dickinson; Franklin Lakes, NJ), the cells were
disloged from the plate and mixed thoroughly with the reagent. Genomic DNA
was sheared by passing the lysate 6-10 times through a 3ml syringe with a 2728 gauge needle. The lysate was transferred into a clean microfuge tube, and
incubated on ice for 5 min. to allow dissociation of nucleoproteins. Two hundred
microliters of chloroform was added and the lysate vortexed for 15 sec and
incubated on ice for 10 min. The lysate was centrifuged at 14,000 rpm for 10 min
at 4°C. The upper aqueous phase was collected, without disturbing the
interphase, by aspirating gently with a micro pipetter and transferred into a clean
microfuge tube. The bottom phase was discarded, or could be saved for future
genomic DNA isolation. One half and ml of isopropanol was added and mixed by
inversion several times to allow RNA precipitation. The precipitation reaction was
incubated at room temperature for 10min and then centrifuged at 14,000 rpm for
15 min at 4°C in an Eppendorf 5417C centrifuge. A white pellet should be
observed, and the supernatant discarded carefully without dislodging the pellet.
Resuspending the pellet in 1ml of cold 75% ethanol and centrifuging for 14,000
rpm for 10 min at 4°C in an Eppendorf 5417C centrifuge washed the RNA pellet.
The washed RNA pellet was then dried in a speedvac (Savant SVC-100H;
Holbrook, NY) for 5-min. However, caution has to be used so as to not over dry
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the pellet. The pellet was dissolved in 0.5% SDS at 65°C for 10 min and stored at
-80°C.
1. Quantitation of RNA
Two microliters of RNA sample was diluted with 98pl of ddb^O (pyrogen
free) treated water (1:50). This dilution was quantified in a Beckmann DuPont
650 spectrophotometer at Aaeonm. The RNA concentration was calculated using
the following formula:
pg/ml = A260 x 50 (dil. Factor) x 40 (RNA Factor)
The purity was measured by obtaining the A26o/28onm ratio and electrophoresing
1pg on a 1% denaturing agarose gel.
The gel was prepared as follows in a fumehood because of the
formaldehyde. Mix in this order 1) agarose (NuSieve GTG; FMC, Rockland, ME)
- 3.5g, 2) ddH20 - 304.5ml, 3) 10X 3-(N-morpholino)propanesulfonic acid
(MOPS) - 35ml, 4) 37% formaldehyde (J-T Baker, Phillipsberg, NJ). The agarose
was dissolved using a conventional microwave oven and the mixture cooled to
50°C, then 10 ml of 37% formaldehyde added. Fresh gel loading buffer was also
prepared for each sample as follows: 10X MOPS - 5pl, 37% formaldehyde (J T
Baker) - 8.75pl, formamide (J-T Baker, Phillipsberg, NJ) - 25jJ, ethidium
bromide (10mg/ml) - 0.2pl) and RNA + DPEC H20 - 11.25^1. The samples were
heated to 55°C on a heating block and 10pl of gel loading buffer (50% glycerol,
1mM EDTA, 0.4% Bromophenol Blue, 0.4% Xylene Cyanol) added/sample. The
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samples were loaded carefully into the wells and the gel electrophoresed at 100V
until dye migrated halfway down the gel. The RNA was then observed under a
UV light source (Alpha Innotech Corp; IS-1000 Digital Imaging System, San
Leandro, CA).
P. Single Step Reverse Transcriptase-Polymerase Chain Reaction
The kit utilized for all RT-PCR experiments was the ProSTAR™ HP (High
Fidelity) Single-Tube RT-PCR System (Stratagene; La Jolla, CA). Control and
experimental reactions were prepared by adding the following in order into thin
walled sterile PCR tubes (Molecular BioProducts, San Diego, CA). When multiple
samples were being analyzed, a master-mix cocktail containing all the reagents
except the variable, was prepared and aliquoted out into the PCR tubes. All the
reagents were added in the following order, making sure that NO CROSS
CONTAMINATION occurred. Cross contamination was prevented by designating
different areas for either aliquoting PCR reagents, preparing master mix solutions
or setting up the PCR reactions. The protocol outlined below will suffice for a
control and an experimental reaction. A detailed protocol can be found at:
http://www.stratagene.com/manuals/600164.pdf
The control reaction was prepared alongside all experimental reactions to
serve as a positive control for the efficacy of the reagents. The following was
prepared in order: 40.5|ul of RNAse free water (NO DPEC), 5pl of 10X HF RTPCR Buffer, 1pl of control primer set (200ng/ml), 1pl of dNTP mix (40mM), '\[x\ of
control mRNA. The Moloney murine leukemia virus reverse transcriptase
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(MMLV-RT) was diluted as outlined in the protocol with HF RT-PCR buffer and
ddHaO and 1pl added to each reaction. 0.5pl of TaqPlus Precision DNA
polymerase mixture was added to each reaction in the last step. The tubes were
vortexed gently, ensuring no bubbles formed and placed into an automated
thermal cycler (Perkin Elmer; Norwalk, Connecticut) using the program outlined
below (Table 1).
Thermal
Cycler

Cycles

Temperatu
re

<2kb
target

>2kb
target

Single block

1

37°C

15 min

30 min

RT
Inactivation

1

95°C

1 min

1 min

40

95°C

30 sec

30 sec

60°C

30 sec

30 sec

68°C

2 min

2 min/kb

68°C

10 min

10 min

Annealing

1

Table 1 shows the PCR thermocycler setup, fo
standard RT-PCR reactions.
The experimental reaction was set up in the same manner as the control.
Depending on the particular experiment, either the primer templates or RNA
samples were the variable and, thus, added last into the mixture. Briefly, 39.5pl
of RNAse free water (NO DPEC), 5pl of 10X HF RT-PCR Buffer, 1pl of upstream
primer (1 OOng), 1 pi of downstream primer (1 OOng), 1 pi of dNTP mix (40mM), 1 pi
of RNA (200ng), 1.0pl of the diluted MMLV-RT to each reaction and 0.5pl of
TaqPlus Precision DNA polymerase was added to each reaction. The samples
were vortexed gently without the creation of bubbles and placed in a thermal
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cycler. The primers used for the amplification of TGF-pi, TGF-p2, TGF-p3 and
murine IL-2 are shown below (Table 2), along with Tm’s (Tm = 2AT + 3GC) used
for amplification.
Table 2
Product
TGF-pi (Park
etal., 1997)
TGF-P2 (Park
etal., 1997)

Primer Sequence

Tm

Expect
ed Size

Sense: S’-GACCGCAACAACGCCATCTA-S’

65°C

236 bp

65°C

441 bp

65°C

365 bp

62°C

223 bp

Antisense: 5’-GGCGTATCAGTGGGGGTCAG-3
Sense: 5’-GGAAAGCCAGGACACGAAAATCACG-3’
Antisense:5’-GCAATACAGAGGAACCAGGAAGAGG-3’
Sense: S’-TGTGGGTTGGTTAGGGGAAGG-S’

TGF-P3 (Park
et al., 1997)

Antisense: 5’-TGCTGATCGAGGTGAAAGAC-3’

Murine IL-2

Sense: 5 - GTCACATTGACACTTGTGCTCC 3’
Antisense: 3’ AGTCAAATCCAGAACATGCCG 5’

After completion of the PCR, the reaction products were stored at -20°C
until needed or analyzed using electrophoresis with a 1% agarose gel. The
products were readily visible by UV transillumination of the ethidium bromidestained using the Alpha Innotech Imager.
Q. Animals
Inbred BALB/cByJ, 6-8 weeks old, were originally obtained from the
Jackson Laboratories, Bar Harbor, ME. The animals were kept in shoebox cages
(4-5/cage) in a room controlled for humidity, temperature and 12hr light/dark
cycle. Food and water were provided ad libitum. They were maintained in the
Animal Care Facility of Loma Linda University, Department of Microbiology &
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Molecular Genetics. The institutional Animal Care and Use Committee approved
all protocols. In all the experiments that involved H238 tumor development, mice
were randomized in groups having 5-8mice/group. A separate group was set
aside as un-injected controls.
R. Tumor Propagation and Measurement
Wild type or transfected H238 cells were diluted to 5 x 106 cells/ml using
the trypan blue exclusion method and resuspended in sterile PBS buffer. This
ensured that only viable cells were used for tumor implantation. Mice were
inoculated sub-cutaneously (s.c.) in the right hind leg with 5 x 105 cells/1 OOpI
using a sterile tuberculin syringe. Un-injected mice served as normal host
controls. Tumor dimensions were measured using vernier calipers and the length
(L), width (W), and height (H), of each tumor was used in the following
calculation: tumor volume (mm3) = (L x W x H)/2. This formula has been used
previously for the measurement of solid tumors (Gridley et al., 1982; Gridley et
al., 1987).
T. Spleen Cell Preparation and Peripheral Blood Collection
Mice were euthanized using C02 asphyxiation and peripheral blood
collected via cardiac puncture using tuberculin syringes with approximately 10pl
of heparin (Life Technologies, Rockville, MD). The spleen was removed using
aseptic technique and placed in 4ml snap cap tubes (Falcon, Franklin Lakes, NJ)
containing 1ml of RPMI-1640 media (Hyclone Laboratories, Logan, UT)
supplemented with 10% heat inactivated (55°C) BCS, genatmycin (50pg/ml)
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(Sigma, St. Louis, MO) and fungizone (100[ig/ml) (Sigma, St. Louis, MO). Whole
spleens were processed into a single cell suspension using sterile applicator
sticks and filtered through a 40pm cell strainer (Becton Dickinson, Franklin
Lakes, NJ), to remove any tissue debris. Erythrocytes were removed by
treatment of the spleen cells with 1ml of ammonium-chloride-potassium (ACK)
lysing buffer for 4min at 4°C. The leucocytes were washed 3 times in RPMI-1640,
resuspended in 1ml of RPMI-1640 media and viable cells counted using the
trypan blue exclusion technique using a hemocytometer as shown below.

A

D

B

G

Number of cells in sections A, B, C
and D are counted. Viable cells are
usually identifiable by the silver
halo around them.
Cells/ml = # of cells x 104 x dilution
factor
4

S. Mitogen Titration
Phytohemagglutinin (PHA; Sigma Chemical Co, St. Louis, MO),
concanavalin A (ConA; Sigma Chemical Co, St. Louis, MO), pokeweed (PW;
Sigma Chemical Co, St. Louis, MO) or lipopolysaccharide (LPS, Sigma Chemical
Co, St. Louis, MO) were diluted as shown in Fig. 9A in a 96 well plate and
dispensed 100pl aliquots. A spleen was obtained from a non-tumor bearing
mouse and processed into an erythrocyte-free single suspension as described
above. The splenocytes were diluted to 2 x 106 cells/ml and dispensed at
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Fig. 9 Template setup to determine the optimal
dilution factor for the mitogens. The dilutions were
carried out as described in panel A. Panel B shows
the arrangement of the splenocytes from different
animals to evaluate their mitogen-stimulated
proliferation Index.
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lOOjil/well. The plates were incubated at 37°C in a humidified incubator for 72
hrs, and then pulsed with 50pl of 1pCi 3H-Thymidine (3H~TdR specific activity =
50Ci/mmol; ICN Radiochemicals Inc., Irvine, CA) for 4hrs. The cells were
harvested using an automated multiple sample harvester (Brandel, Gaithersburg,
MD). Discs were cut out from the filter paper, representing individual samples,
and placed into scintillation vials with 2ml of scintillation fluid (CytoScint; ICN
Radiochemicals Inc., Irvine, CA). 3H-TdR incorporation was measured using a
beta scintillation counter (Beckman, Inc., Fullerton, CA). The results were
expressed as disintegrations per minute.
The MTS assay was also used in tandem to evaluate the efficiency of 3HTDR uptake and to validate the results obtained from 3H-TdR. The spleen cells
were processed as described above. However instead of adding 50pl of 3H~TdR,
40pl of the MTS reagent was added. The plate was incubated for 2 hrs at 37°C to
allow for an optimum oxidation reaction, and the plate read at 490nm in a
Benchmark Microplate Spectrophotometer (Biorad).
U. Mitogen Stimulated Spleen Lymphoblastogenesis Assay
Spleen cells from tumor bearing and non-tumor bearing mice were
harvested and processed as described above, diluted to 2 x106 cells/ml and
100pl aliquots added to each well. Mitogens were diluted to the optimum
concentration, pre-determined from the titration, and added to each of the wells,
according to the template in Fig. 9B. The plate was incubated at 37°C in a
humidified incubator for 72hrs and pulsed with 50pl of 1pCi 3H-Thymidine (3H-
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TDR; specific activity 50Ci/mmol; ICN Radiochemicals Inc.) for 4hrs. The cells
were harvested using the Brandel automated cells harvester protocol as outlined
above and 3H-TdR uptake expressed as dpm. A Stimulation Index (SI) was
calculated using the formula:
SI = dpm from mitogen stimulated cells - dpm from non-stimulated cells
dpm from non-stimulated cells
V. Tumorigenicity of H238 tumor cells
H238 cells were trypsinized and resuspended as a single cell suspension
as described above. Cells were resuspended in three groups having
concentrations of 1 x 105, 5 x 105and 1 x 106 cells/1 OOpI in sterile PBS. Each
group of cells was injected into four BALB/c mice. The experiment also included
four un-injected animals which served as untreated controls. Palpable tumors
were allowed to form for an initial two weeks. Thereafter, tumor measurements
were initiated until the tumors reached a volume of >1000mm3 (the maximum
volume allowed by the Loma Linda Animal Care Facility). The mice were
sacrificed by C02 asphyxiation and the spleens harvested. The spleens were
weighed and then processed into single cell suspension as described above. The
splenocytes were added into 96 well microtiter plates containing pre-titrated
mitogens, and proliferation was measured by 3H-TdR uptake as described in the
Mitogen Stimulated Spleen Lymphoblastogenesis Assay
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W. Flow Cytometry Analysis of Lymphocyte Populations from Splenocytes and
Peripheral Blood
Splenocytes were obtained by processing harvested spleens according to
the protocol mentioned above. These were phenotyped using the
FACSCalibur™ 4 channel dual laser flow cytometer (Becton Dickinson, Inc.
Franklin Lakes, NJ) and analyzed using the CellQuest software v. 3.1 (Becton
Dickinson, Franklin Lakes, NJ). The assay, in principle, relies on the ability of the
flow cytometer to identify and count cells stained with antibodies conjugated to
various florochromes. The florochromes used were fluorescein isothiocyanate
(FITC), phycoerythrin (PE), allophycocyanin (APC) or peridinin chlorophyll II
protein (PerCP). The populations were defined on parameters such as
granularity (side scatter - SSC) versus CD45 (common leukocyte antigen).
Populations of cells expressing a combination of these two characteristics were
“gated” and then further resolved to subpopulations based on staining with
antibodies such as anti-CD3, CD4, CDS, B220 and pan NK. Lymphocyte
activation was measured by the expression of surface markers associated with
activation such as CD71 (transferrin receptor) and CD25 (IL-2 receptor). Using a
combination of both panels it can be possible to resolve specific populations of
activated lymphocytes. All antibodies/cocktails used were purchased from
Pharmingen/BD (San Diego, CA), and were prepared as cocktails as follows:
CD3-FITC/CD8~PE/CD45~PerCP/CD4-APC
CD3-FITC/Pan NK-PE/CD45-PerCP/B220-APC

75

CD25-FITC/CD71 -PE/CD45-PerCP/CD3-APC
FITC:

fluorescein isothiocyanate

PE:

R-phycoerythrin

PerCP:

peridinin chlorophyll protein

APC:

allophycocyanin

The antibodies were directed against the following markers: CD45 common leukocyte antigen, CDS - T cell receptor-associated protein present on
all mature T cells, CD4 - T cell protein found on the T-helper population of cells,
CDS - T cell protein found on the T-cytotoxic/suppressor population of cells, B220
- B cell marker, pan NK - protein associated with all natural killer cells, CD71 Trasferrin receptor expressed on activated leukocytes and CD25 - IL-2 receptor
expressed on activated lymphocytes.
The technique was based on the “Lyse/No-Wash Staining Protocol”,
developed by Pharmingen (Landay & Muirhead 1989). Prior to beginning this
protocol, tubes were labeled with sample name and antibody used. Blood
samples to be analyzed were collected in tuberculin syringes with 0.1ml of
heparin/1 ml of blood (10units/ml), via cardiac puncture, to prevent clotting and
then diluted 1:2, approximating between 105~ 106 cells/ml. Spleen cells were
processed as described above, and diluted to approximately 1 x 106 cells/ml. All
the samples were diluted using PBS (room temperature) and mixed gently on a
vortex mixer. The samples were aliquoted (100pl) into the appropriate series of
tubes for each specimen and the non-specific regions of the sample were
blocked using 10jnl of diluted Fc block (1:5 dilution (0.1 mg/ml) from stock vial
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(0.5mg/ml) using sterile PBS), added to the side of the tube to prevent the
addition of double or no antibody to the tubes. Post Fc blocking the tubes were
vortexed to mix all the samples and incubated on ice for 10 min. Ten microlitres
of the diluted monoclonal antibody cocktail (if stock vial is 0.5mg/ml, then dilute
1:5 for final concentration of 0.1 mg/ml, if the stock concentration is 0.2mg/ml,
then dilute 1:2 for final concentration of 0.1 mg/ml with sterile PBS) was added to
the side of the tubes as before, the tubes mixed gently on a vortex mixer and
incubated on ice for 15 min in the dark to prevent “capping”. During the mixing
step, 3mls of freshly diluted lysing solution (1X) was added to lyse erythrocytes
and the tubes centrifuged at 1800rpm for 5 min. The supernatant was carefully
removed and the cell pellet was resuspended in 500pl of PBS. The cells were
resuspended in a vortex mixer, capped and stored in the dark at 4°C. The
samples were analyzed on a pre-calibrated FACSCalibur™ machine and the
data analyzed using the CellQuest software. The number of lymphocytes in each
population was calculated using the following formula:
# of cells in population/ml = # of lymphocytes/ml x percentage of population
X. In vitro growth analysis with exogenous TGF-p
A stock of TGF~[31 (R & D Systems, Minneapolis, MN) was prepared by
diluting 2pg of TGF-pi in 1 ml in 4mM HCI + 1 mg/ml of BSA to have a final
concentration of 2ug/ml or 2ng/pl. Stock TGF-pi (97.5pl) was mixed with 38.9ml
of serum free media was mixed and 200pl aliquoted to row C. Serum free media
(100pl) was added to the rest of the plate and a 1:2 serial dilution (5ng/ml to
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0.15625 ng/ml) was performed as outlined in fig. 10A. Two similar plates were
prepared (I & II). Anti-TGFp1 antibody (R & D Systems) was reconstituted in 1ml
of PBS to yield a final concentration of 1mg/m and kept on ice. Two tubes (A & B)
of H238 cells (pre-conditioned in serum free media for 48hrs) were prepared at
concentration of 5000 H238 cells/1 OOpl/well (5 x 104 cells/ml in a total volume of
20ml). Cells from tube A (100pl) were added to plate I, without any antibody.
To ensure complete blocking of the TGF-|31 by the antibody, 600ng/ml of
antibody was added to tube B of H238 cells and 100pl was aliquoted into a plate
II. The rationale behind the antibody concentration was based on the 6-fold
difference between the molecular weight (MW) of TGF-p (25kDa) and that of the
antibody (150kDa); thus, 60ng of antibody would be required to block 10ng of
TGF-p1. To ensure absolute blocking, a 10 fold greater concentration of antibody
was used (600ng/ml). Four plates were prepared, one plate for each day of the
assay (Fig 10B).
The plates were incubated at 37°C and proliferation was assayed using
either MTS or 3H-TDR. For the MTS assay, 100pl of the media was removed
prior to adding 20|il of the MTS reagent. The plate was incubated for 2 hrs in the
dark and assayed at 490nm. For the 3H-TDR assay, 50pl of the 3H-TDR (ICN)
was added to the wells and incubated for 4 hrs. The cells were harvested using
the 96 well automated harvester (TomTech, Handen, CT). Attached cells that did
not come off during the wash steps were removed by adding 150pl of 1x and, if
necessary, 10x trypsin, incubated for 15-25 min at 37°C, visualized under an
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Fig 10. Plating template for H238 cells to measure
any growth modulatory effect on H238 cells. TGF-p
was diluted as described and added to the plates in
concentrations ranging from 5ng/well to 0.15ng/well.
The cells were set up according to the method
described at a concentration of 5 x 103 cells/well.
Control wells were included where no TGF-p or cells
were plated (Panel A). A second plate was also
prepared Fig 10B, identical to the first except that 600ng
of anti-TGF-p antibody was added as described. This
plate served as a control for TGF-p to confirm any
modulation of growth due to it.
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m

inverted microscope to verify detachment and re-harvested.
Y. Protein Extraction
Eithr H238 or CCL-64 cells were propagated in complete media as a
monolayer in a 100mm tissue culture dish (Falcon), 24hrs prior to extraction. The
media was aspirated and the cells washed with PBS. Lysis buffer (25ml = 50mM
Tris-HCI, pH 7.5, 150mM NaCI, 1% Nonidet P40/0.5% sodium deoxycholate, 1
Complete™ tablet (1 mM phenylmethanesulfoynl fluoride (PMSF), 1 pg/ml
leupeptin, 1 pg/ml benzamidine, 1 pg/ml pepstatin and 5 pg/ml aprotonin; Roche,
Indianapolis, IN) was added (1-3mls) to the dish, and the cells detached from the
plate using a sterile plastic policeman (Becton Dickinson). The lysate was
collected into a 2ml microfuge tube. The tube/lysate was boiled for 3-5 min
making sure that the water level in the bath covered at least 50% of the tube,
thus preventing the ‘popping’ of the microfuge lid. The tube was centrifuged for
approximately 1 min to pellet any cellular debris, aliquoted at 150pl/microfuge
tube and stored at -20°C. A 50jil aliquot was kept aside to measure protein
concentration described below.
Z. Protein Quantification
The template was set up as shown in Fig 11. Twenty microliters of Bovine
Serum Albumin (BSA; Roche) standard (2mg/ml) or undiluted sample was added
into first column of a 96-well microtiter plate. One hundred and eighty microliters
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Fig. 11 96-Well Template used to set up Protein Quantitation
S = Standard, X = Experimental Samples
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of H20 was added into the above wells to bring up the volume to 200jal. To all the
other wells, until column 7, 10OpI of water was added. A serial dilution (1:2) was
performed for the standard and all the samples, until column 7. The Biorad
Protein Assay Reagent (Biorad) was diluted 1:4 (2ml of reagent + 8ml of PBS)
and 100pl of the diluted reagent added to each well. The plate was incubated at
room temperature for 10 min and assayed using the Benchmark Microplate
Spectrophotometer (Biorad) set at 570nm.
AA. Immunoprecipiatation of TGF-pRII and TGF-pRI
Whole cell lysate (25pl) from either H238 or CCL-64 cells was brought up
to 500pl with PBS and 10jig/ml of anti-TGFpRII (Upstate Biotech, Lake Placid,
NY) or anti-TGFpRI (Santa Cruz Biotech, Santa Cruz, CA) antibody added and
incubated overnight at 4°C with constant agitation. The bound complex was
precipitated with a 100pl of protein-A agarose (Gibco/Life Technologies,
Rockville, MD) by thorough mixing. This was incubated for 1hr at 4°C with
constant agitation. The beads were centrifuged for 10 min at 6000rpm, and then
pulsed for 15sec at 14,000rpm. The supernatant was discarded or can be stored
at -20°C for analysis of other proteins. The protein A bead pellet was
resuspended in 1ml of immunoprecipitation buffer (100ml = 0.5% Tween 20 500pl + 50mM Tris 605.5mg + 150mM NaCI - 876.6mg + 0.1mM EDTA 3.72mg) and washed by centrifuging at 6000rpm for 10min. The supernatant was
discarded. This was repeated 3 times culminating with a final wash with water.
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The beads were incubated at room temperature for 30 min in 35-40pl of lysis
buffer (IP Buffer + 5mM DTT + 150mM p-mercaptoethanol + 1% Triton X + 3%
SDS), depending on the initial amount of total protein and the endogenous
expression level of the protein of interest. Centrifuging the beads at 10,000rpm
for 5min allowed collection of the supernatant, which was removed carefully
using a pipettor with protein gel loading tips and store at-70°C until used.
AB. Isolation of Eukaryotic Membranes
H238 or CCL-64 cells were resuspended in 200pl of HBSS with 0.2% BCS
and washed twice in the same buffer by centrifuging at 10,000rpm for 1 min,
discarding the supernatant and resuspending the pellet in HBSS. The final cell
pellet was resuspended in 200pl of IP buffer, lysed by 2 cycles of freeze/thaw in
liquid nitrogen and sheared with a tuberculin syringe assembly. Cellular
membranes were then isolated by ultracentrifugation at 100,000g for 1hr at 4°C
using a Ti-90 rotor with a Beckman XL90 ultracentrifuge. The membrane pellet
was resuspended in 220pl of IP buffer with 2% NP-40 and incubated on ice for
30min. Twenty microlitres of protein was removed for protein quantification as
described earlier. The rest of the samples were immunoprecipitated as outlined
earlier. If long term storage was desired, the pellet could be stored at -80°C.
AC. RT-PCR analysis of TGF-p Type I and II receptors
Total RNA was extracted from either H238 or CCL-64 cells and
quantitated as described earlier. A RT-PCR reaction was set utilizing the protocol
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outlined above, however, the following set of primers was used for either TGF-p
receptor Type 1 or TGF-p receptor Type 2 (Table 3).
Table 3
Product

TGF-pR1

Lowsky et al,
2000

Amoroso et al.
1998

Lowsky et al.
2000

TGF-pR2

Primer Sequence

Reference

Amoroso et al,
1998
S1

Sense: 5’ GCTGCTTT CAGGTTT AT GAG 3’

Tm

Expected
Size

55°C

217 bp

65°C

761 bp

55°C

287 bp

60°C

961 bp

60°C

483 bp

60°C

461 bp

60°C

485 bp

Antisense: 3’ GATGCAAGCTAAAAGACATA 5'
Sense: 5’ TCCGCAGCTCCTCATCGTGTT 3’
Antisense: 3' CTGCGTCCATGTCCCATTCTCTT 5
Sense: 5’ CTCACCTACCACGGCTTCAC 3’
Antisense: 3’ CT CAGCTT CT GCTGCCGGT G 5’
Sense: 5’ TTGCCAT AGCTGT CATCATCATCTT CT 3’
Antisense: 3’ GGGGCTCGTAATCCTTCACTTCTC 5’
Sense: 5’ TGAGAGGGCGAGGAGTAA AG 3’
Antisense: 3’ CGA GTGGATGGTGCCGAAG 5’

S2

Sense: 5’ ACCCCA AGCTCA CCTACCAC 3’
Antisense: 3' CTCCAGATGTTCCGGTTCGAC 5’

S3

Sense: 5' GCGCCA ACAACATCA ACCACA 3’
Antisense: 3’ GACAACGGACACACTGAAGCCC 5’

AD. Western Blot Protocol with Pierce ECL Detection method

1. Reagent and Gel Preparation
One liter of gel buffer pH 8.45 (1 liter) was prepared as follows: (Tris 181.71g + SDS - 1 ,5g + Glycerol - 200g). The pH was adjusted with
concentrated HCI. The anode and cathode buffers were prepared in 4 liter bulk
solutions as follows. The anode buffer (0.2M Tris, pH 8.9) was prepared by
dissolving 96.91 g (24.23g/L) Tris [or 387.64g for 4L of 4X] in ddH20. The pH was
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adjusted with concentrated HCI. The cathode buffer (0.1 M Tris, 0.1M Tricine,
0.1% SDS, pH 8.25) was prepared by mixing 48.46g (12.11g/L) Tris + 78.87g
(19.72g/L) Tricine + 4g (1g/L) SDS. No pH adjustment was necessary. Stock
solutions were prepared as 4X of the above. The transfer buffer was prepared as
follows: (12mM Tris, 96mM glycine, 10% methanol pH 8.3). The SDS
polyacrylamide gels were prepared as follows by adding the following reagents in
order as shown in the table below:
MINI GEL

Separating Gel

Stacking Gel

30.2% Acrylamide

1.67 ml

273 |nl

Gel Buffer

3.33 ml

1.034 ml

Water

n/a

0.77 ml

10% AmPerS04

25 pi

16.7 pi

TEMED

2.5 pi

1.67 pi

2. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE)
One dimensional Tris-tricine SDS-PAGE of proteins was performed
according to Schagger and von Jagow (1987). Cells grown in 100mm tissue
culture dishes were harvested and washed with PBS. Protein was extracted
using the procedure outlined above. Either 1.5pl or 2.5p! of whole cell lysate was
brought up to 10pl in sample buffer (0.125 M Tris-HCI pH 6.8, 20% glycerol, 4%
SDS, 0.006% bromophenol blue and 20 pi beta-mercaptoethanol/ml buffer) and
boiled for 5-10mins. Samples were separated for 1.5 hrs (or until the pre-stained
molecular weight standards clearly separated) from a Hoefer PS500XT power
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supply (Hoefer Scientific Instruments, San Francisco, California) at 15V on 10 cm
x 8 cm 12.5% Tris-tricine polyacrylamide separating gel with 5% stacking gel in a
BioRad Mini Protean Gel Apparatus (Richmond, California). A 5 fil aliquot of pre
stained low molecular weight standards (BioRad Laboratories, Richmond,
California) was also separated on each gel.
Following the electrophoresis, the gel was either stained using coomasie
brilliant blue staining solution (0.25% coomassie brilliant blue, 45.4% methanol,
9.2% glacial acetic acid) for 30 min and destained with 45.4% methanol, 9.2%
glacial acetic acid (Weber and Osborne, 1969) or transferred to nitrocellulose
paper (BioTrace®NT, Gelman Sciences, Ann Arbor, Michigan) as described
below. The gel was removed from the cast and soaked in transfer buffer (12 mM
Iris, 96 mM glycine, 10% methanol, pH 8.2) for 2 min in a clean tray. The Biorad
semi-dry transfer apparatus was set up as follows; the plates were wiped with
paper towels pre-wetted in transfer buffer and three pieces of pre-wet 3M
Whatman paper cut to the size of the gel placed in the center of the plate. A
piece of nitrocellulose cut to the same size of the gel was pre-wet in transfer
buffer. The gel was aligned on the nitrocellulose paper while still in the transfer
buffer and placed on the 3M filter paper stack (gel facing away from the cathode
- towards you) after cutting the bottom right hand corner. All air bubbles were
removed by rolling a clean pipette over the stack. Three additional pre-wetted
filter papers were placed on top of the stack and the transfer initiated for 25 mins
at 15V. The gel was carefully removed and stained in commasie brilliant blue
staining solution for 30 min to verify complete transfer of the proteins.
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AE. Western Blot
The nitrocellulose was placed in a tray with blocking buffer (5% milk with
TBST (25mM Iris, 150mM NaCI, 0.05%Tween20, ph 7.6) buffer for 1 hr at room
temperature with constant agitation. This step could be extended to an overnight
incubation if limited by time. The membrane was washed twice in 15ml of TBST
for 10 min each with agitation. After washing, 10-15ml of hybridization buffer
(TBST + 1ug/ml of primary antibody) was added and incubated for 1 hr at room
temperature with vigorous shaking. The membrane was washed as before and
incubated with secondary antibody (a goat anti-rabbit IgG linked to horseradish
peroxidase (HRP), 1:3000 dilution - donated by Guiseppe Molinaro;
manufactured by BioRad Laboratories) in TBST for 30min to 1 hr at room
temperature with agitation. The membrane was washed again as before and
incubated with equal volumes of luminol and horseradish peroxide (SuperSignal
Chemiluminescent Substrate Detection reagents, Pierce Chemical Co., Rockford,
Illinois) per signal substrate working solution for 2 mins to allow HRP reaction.
The membrane with no air bubbles trapped was taped into the developing
cassette. The results were obtained by exposing the membrane to X-ray film cut
to the exact size of the membrane for an initial 30 sec. Longer exposure were
also used depending on the strength of the signal.
AF. Immunocytochemistry Protocol
H238 cells were propagated at 65-75% confluency in 2 well tissue culture
slides (Labtek, Campbell, CA) 24 hrs prior to staining. On the day of staining, the
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media was removed and the cells gently washed with approximately 300pl of
PBS. The cells were fixed by adding SOOpI of 70% EtOH and the slides were
incubated at -20°C for 15 min. The cells were rehydrated by adding PBS gently
and incubatimg for 5 min at 4°C. The wells were blotted dry by placing the edge
against a paper towel and placed into a wet box (plastic pipette tip box with water
in the base). It is very important not to let the slides become dry at this point as
this may result in significant background staining. The primary antibody was
diluted in PBS to a concentration of 10pg/ml (or as recommended by the
manufacturer) and using a transfer pipettor distributed equally between the wells
(approx. 300pl/well). The wet box was placed at 4°C overnight. The well chamber
was snapped off and the rubber seal removed completely to expose the cells.
The slide was washed by thoroughly dipping 10-15 times into wash solution I.
PBS + 0.05% Azide + 0.5% Tween solution and was solution II. PBS + 0.05%
Azide solution. To ensure thorough washing, the slides were submerged
completely into wash solutions. The secondary antibody (2pg/ml) was added to
the cells carefully, to prevent dislodging the cells. Controls were included with
either no primary, secondary or tertiary antibodies; PBS was substituted. The
slides were incubated over night at 4°C or for 2 hrs at room temperature. They
were washed as before and if signal amplification was required; a tertiary
antibody was used at a concentration of 5pg/ml, incubated over night at 4°C and
washed as before. Drops of propidium iodide (PI; Sigma Chemical Co.) was
added for EXACTLY 5min to stain the nuclei, and washed off as described
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earlier. One drop of permafluor (Immunon, Pittsburgh, PA,) was added on to a
cover slip and placed drop face down onto the slide. Equal but strong pressure
was applied to the cover skip to allow for even set and the slide left drying
overnight in the dark.
AG. Laser Scanning Cytometry
Cells stained using the procedure described above were analyzed using a
microscope based multiparameter laser scanning cytometer (Compucyte Corp,
Cambridge, MA) interfaced with a PC based Wincyte™ software. Multiple sorters
detected fluorescence emitted from stained cells after excitation with an argon
laser. The cytometer was set to count approximately 2-5 x 103 cells, identified by
the red stained nuclei from the PI. A fluorescence intensity contour level was
then determined to include the projected cell area (centered on each nucleus) for
cells positive for green fluorescence. The intensity of the green fluorescence
was then reported as a cell frequency versus fluorescence intensity histogram. A
major proportion of acquisition of this data and the analysis was done with the
assistance of Dr. L. Green (LLU, Radiobiology Program).
AH. Statistical Analysis
The data was assessed using one way analysis of variance (ANOVA),
Tukey’s HSD (honestly significantly difference test), and the non-parametric
Kruskal-Wallace test. A p value of <0.05 was taken to indicate significant
differences. These analyses were performed using SPSS version 8.0 software
(Chicago, IL).
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RESULTS
A. Tumorigenicity of H238 cells
H238 tumorigenicty was determined by diluting H238 cells in a 10-fold
pattern to different concentrations and injecting a known number into BALB/c
mice in the right hind leg as described in the Materials and Method section. Once
palpable tumors appeared (approximately two weeks), tumor development was
measured and recorded as described. Groups of mice injected with H238 cells at
dosages of >5 x 105 cell formed large tumors. In addition, mice injected with 1 x
103 - 5 x 104 H238 cells did not form any significant tumors (data not shown).
BALB/c mice injected with 1 x 106 H238 cells had to be sacrificed at an early time
since the tumors had broken the skin and started to undergo necrosis (Fig. 12).
Therefore to maintain a bearable tumorigenic load by the BALB/c mice, and be
within the limits set by the Animal Care Facility, all in vivo experiments further
described used of 5 x 105 cells/animal.
One measure of the tumorigenicty of the H238 tumor load was obtained
by measuring the spleen weight post sacrifice. Increasing splenomegaly was
observed in groups with larger tumor volumes which corresponded to larger
H238 inocula used (Fig. 13) further corroborating the results by Gridley at al.
(1993)
To confirm earlier studies, which identified TGF-p as the primary agent
involved in suppressing the immune system, total RNA was extracted from H238
cells and the mRNA of TGF-p1 was amplified using RT-RCR. In addition,
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Fig. 12 Antigenicity of the H238 cell line. H238 cells were
injected at different concentrations to determine the
tumorigenic dose of H238 cells. Mice injected with 1 x 106
cells, were sacrificed when the tumors started to necrose.
Animals injected with less then 1 x 105 cells did not form any
tumors (data not shown). For all further experiments, the tumor
forming H238 inoculum used was 5 x 105 cell/mouse
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Fig. 13 Relationship between different tumorigenic doses
of H238 cells and spleen weight post sacrifice. Six week
old BALB/c mice (n=4) were injected with either 1 x 105 or 5 x
105 H238 cells. An uninjected control was included. Mice
injected with higher doses of H238 cells showed significantly
larger spleens when compared to the uninjected control. This
was observed also as dose dependent effect. *Significantly
different from the control (p<0.05)
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primers for the other isoforms, TGF-p2 and TGF-p3, were also used to
investigate co-expression (Park et al., 1997). The amplified products were
separated using electrophoresis on a 1% agarose gel (Fig. 14). Distinct bands
corresponding to the type 1 (236bp), 2 (441 bp) and 3 (365bp) isoforms of TGF-p
were observed. The bands obtained were compared to results from the original
publication, and they appeared to match perfectly.
B. Construction of Plasmid Vectors
All constructed plasmid vectors were based on the pc3 (Fig 15A)
backbone (Invitrogen). The cDNA for IL-2 was excised from the VR1110 plasmid
(obtained from Dr. S. Parker, Vical Inc. San Diego) using the Kpn I and Pst I and
cloned into the pc3 plasmid into the same sites. The orientation of the inserts
was verified using restriction digestions and finally sequenced to verify these
results. The final construct was called pcmlL-2 (Fig. 15C).
The antisense plasmid was constructed using the cDNA for TGF-p1
cloned in an opposite orientation into the pc3 plasmid. The cDNA was removed
from the original plasmid and ligated into the pc3 vector using the Pme I sites.
The orientation was confirmed as before using restriction analysis and
sequencing. The final construct was called pcmasTGF-p (Fig. 15B).
C. Transfection Comparisons
To determine which method of transfection to use for all future
experiments, the calcium phosphate transfection technique was compared to the
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Fig. 14 TGF-p RT-PCR mRNA analysis. RNA was
extracted from H238 using the TRI reagent as described.
Messenger RNA was amplified with the single step RT-PCR
protocol outlined and primers specific for murine TGF-p1
(T1 - 236bp), TGF-P2 (T2 - 441 bp) and TGF-p3 (T3 365bp) specific primers. The bands were compared to
published results and were found to be identical (Park et al,
1996). H238 cells are able to express all three isoforms of
TGF-p.
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Fig 15 Plasmids Constructed. Schematic outline of the A)
pcDNA 3.1 vector (pc3), B) antisense TGF-pi plasmid vector,
pmasTGFpi, and the C) IL-2 expression vector, pcmlL2. CMV
- Cytomegalovirus promoter, BGH pA- Bovine Growth
Hormone polyadenylation signal, SV40 ori - SV40 promoter
and origin, Amp - Ampicilin resistance gene, masTGFp Antisense TGF-p and mlL2 - Murine IL-2 cDNA. Plasmids B
and C were created using standard molecular cloning
techniques and were based on the pc3 (A) vector.
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Superfect® transfection reagent method. These test transfections were
performed in three different cell lines; C6, H238 and CV1 cells, and the
procedures for these have been described. A luciferase expressing plasmid,
pWL7 (donated by Dr. I Fodor), was utilized in measuring the efficiency.
Luciferase expression was found to be significantly greater in all three cell lines
transfected using the Superfect Reagent in comparison to the calcium phosphate
method (Fig. 16). Luciferase expression was approximately 4.5 fold higher in
H238 cells transfected using the Superfect Reagent than in the H238 cells
transfected with calcium phosphate. CV1 and C6 cells showed no measurable
expression of luciferase from cells transfected using the calcium phosphate
method.
To confirm the results obtained using the luciferase construct, the
experiment was repeated using the pcmlL-2 plasmid. H238, C6 and CV1 cells
were transfected using both techniques and media collected every 24hrs until the
cells became 100% confluent. The amount of IL-2 was measured using a
sandwich ELISA. Groups of cells transfected using the Superfect reagent
showed consistent higher expression of murine IL-2 during the course of the
study (Fig 17A) with all the three different cell lines (H238: 1650 vs 1000pg/ml,
CV1: 1150 vs 1000pg/ml, C6: 1250 vs 1000pg/ml). IL-2 expression from H238
and CV1 cells transfected using the calcium phosphate technique was lower then
the previous group (H238: 875 vs 800pg/ml, CV1: 350 vs 100pg/ml). C6 cells did
not express any IL-2 using this method (Fig 17B).
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Fig 16 Luciferase Expression Using Superfect Reagent
and Calcium Phosphate. H238, C6 and CV1 cells were
propagated at a concentration of 5 x 105cells/well and
transfected with pWL7 luciferase plasmid using either
Superfect reagent (Qiagen) or and luciferase detected as
using the assay described. Superfect reagent showed
consistent higher transfection results over the calcium
phosphate technique. *Significantly higher (p<0.05) then the
Calcium phosphate from the same group.
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Fig. 17 IL-2 Expression using either Superfect reagent (A)
or Calcium phosphate (B). H238, C6 or CV1 cells were
propagated at density of 5 x 105 cells/well and transfected
using either of the above two techniques. Media was collected
as described and IL-2 expression analyzed using a sandwich
ELISA. Protein concentration was quantified using a standard
curve. Expression from all three cell lines is significantly
greater (p<0.05) when the Superfect reagent is used as the
transfection modality.
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D. G418 Kill Curve
Prior to creating stable H238 cell lines expressing either murine IL-2 or
antisense TGF-p, the sensitivity of H238 cell to geneticin sulfate (G418) was
determined. H238 cells were plated in media supplemented with different
concentrations of G418. Proliferation of the cells was measured using the MTS
assay. A significant difference in the proliferation of the cells was observed after
72 hours. H238 cells growing in complete media with no G418 showed a normal
growth pattern. However, cells growing in media supplemented with G418 (200 SOOpg/ml) showed less growth with only slight to no proliferation observed (Fig.
18). Microscopic observation showed that cells grown in antibiotic supplemented
media had an abnormal rounded morphology with many of cells being non
adherent. Cells grown in complete media, without G418, showed a normal
adherent morphology. Based on these results, transfected H238 clonal selection
used 700pg/ml of G418. Routine cell culture media for transfected H238 cells
used 500pg/ml of G418.
E. In vitro Expression
Wild type H238, pc3, antisense or IL-2 transfected H238 cells were plated
at a concentration of 5 x 105 cells/well with complete media. An aliquot of
conditioned media was removed every 24 hrs until the cell layer reached 100%
confluency. Thereafter TGF-p (Fig. 19) or IL-2 expression (Fig. 20) was assayed
using the EILSA technique.
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Fig. 18 ‘Kill Curve’ for H2838 cells in response to
geneticin sulfate (G418). From the different dilutions tested,
an average of 500jag/ml of G418 was used for maintenance of
transfected cell cultures. Selection of stable clones utilized
800jag/ml of G418.
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Fig. 19 Temporal TGF-p Expression. H238, pcH238 and
masH238 cells were plated at a density of 5 x 105 cells/well.
An aliquot of media was collected every 24hrs and stored at 20°C. TGF-p expression was analyzed using a sandwich
ELISA technique. Expression of TGF-p was consistently lower
then either expression from H238 or pcH238 cells over the 3
day test period.
* Significantly lower (p<0.05) then the wild type or pcH238
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There was a significant (p < 0.05) decrease in TGF-p expression from
cells transfected with the antisense plasmid, in comparison to either wild type or
pc3 transfected cells. Over the 72 hrs assay period, masH238 cells produced 25
- 350pg/ml of TGF-p, whereas, wild type cells and pcH238 cells produced
approximate 305 - 900pg/ml. A 5-fold decrease in TGF-p expression was
observed in this experiment from masH238 cells after a 48-72 hr growth period
(Fig 19).
IL-2 expression was also quantified using ELISA from the conditioned
media of H238, pcH238 and H238-IL2 cultures. There was no measurable
expression from H238 and pcH238 cell culture supernatants. H238-IL2 cells
expressed IL-2 in the range of 600 - 1400pg/ml over a 72 hr period (Fig. 20). In
addition, no detectable signs of toxicity were observed and cellular morphology
closely resembled wild type cells (data not shown).
To verify these results and to confirm that the antisense TGF-p construct
was indeed blocking the TGF-p transcript, one step RT-PCR was performed on
total RNA extracted from H238, pcH238, masFI238 and H238-IL2 cells. The
primers used for this reactions were obtained from published papers as
described in the Materials and Methods in Table 1 and their specificity confirmed
using BLAST analysis against sequences deposited in the GENBANK (Fig. 21).
Total RNA extracted from H238-IL2 cell cultures showed clear expression of the
IL-2 transcript (223bp) when amplified with IL-2 specific primers, where as RNA
from H238 and pcH238 cells show no amplification (Fig. 22).
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Fig 21 RT-PCR primers for TGF-p1, TGF-p2, TGF-p3 and
murine IL2 aligned using BLAST. The results indicate that
these primers are highly specific to the protein of interest
therefore, all the RT-PCR reactions would be expected to have
specific amplification of the protein of interest. The lower the E
value, the greater the homology between the experimental and
published sequences.
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BLAST for the sequence - (5TGFB13) GAC CGC AAC AAC GCC ATC TA
emb | AJ009862 IMMU009862 Mus xnusculus mRNA for transforming g. . .
gb|M13177|MUSTGFRNA Mouse transforming growth factor beta m. ..
dbj|D78272|CHKM1R Chicken DNA for melanocortin 1-receptor, ...

40
40
34

0.004
0.004
0.26

BLAST for the sequence - (3TGFB15) GGC GTA TCA GTG GGG GTC AG
gb|L42458|MUSTGF1G03 Mus musculus TGF-1 gene, exon 3.
gb|M13177|MUSTGFRNA Mouse transforming growth factor beta m...
emb|AJO09862|MMU009862 Mus musculus mRNA for transforming g...
emb|X52498|RNTGFB1 Rat mRNA for transforming growth factor-...
ref|NM_002738.1|PRKCB1| Homo sapiens protein kinase C, beta...

40
40
40
40
32

0.004
0.004
0.004
0.004
1.0

BLAST for the sequence - (5TGFB23) GGA AAG CCA GGA CAC GAA AAT CAC G
50
emb|X57413IMMTGFB2 Mouse mRNA for transforming growth facto...
36
gb|AC005894|AC005894 Drosophila melanogaster, chromosome 2R...

9e-06
0.13

BLAST for the sequence - (3TGFB25) AGC AAT ACA GAG GAA CCA GGA GAG G
50
emb1X57413|MMTGFB2 Mouse mRNA for transforming growth facto...
34
emb|AL021877|HS101G11 Human DNA sequence from clone 101G11 ...

9e-06
0.51

BLAST for the sequence - (5TGFB33) TGT GGG TTG GTT AGG GGA AGG
gb|U03491|RRU03491 Rattus norvegicus Wistar transforming gr...
gbIM32745IMUSTGFB3 mouse transforming growth factor beta-3 ...
dbj|D26455|TOBTID44 Nicotiana glauca X Nicotiana langsdorff...

42
42
32

0.001
0.001
1.3

BLAST for the sequence - (3TGFB35) TGC TGA TCG AGG TGA AAA GAC
gb|M32745|MUSTGFB3 mouse transforming growth factor beta-3 ...
gb|U03491|RRU03491 Rattus norvegicus Wistar transforming gr...
emb|AL096883.1|HS323M22B Novel human gene mapping to chomos...

42
42
30

0.001
0.001
5.0

BLAST for the sequence - (5IL23) GTC ACA TTG ACA CTT GTG CTC C
gb|K02292|MUSIL2T Mouse interleukin-2 mRNA, complete cds. >...
emb|X01772|MMIL04 Mouse mRNA for interleukin-2 (IL-2)
gb|AF065914.1|AF065914 Mus musculus strain C57BL/6J interle...
gbIM16760IMUSIL2A01 Mouse interleukin 2 (IL-2) gene, exons ...
emb|X01663|MMIL01 Mouse interleukin-2 gene exon 1 and exon 2
gb|L78438|SYNIL2S Synthetic Shiva la precursor gene, interl...

44
44
44
44
44
36

3e-04
3e-04
3e-04
3e-04
3e-04
0.081

BLAST for the sequence - (3IL25) AGT CAA ATC CAG AAC ATG CCG
gb|AF065915.1|AF065915 Mus musculus strain A/J interleukin-...
emb1X73040|MMINTLK2 M.musculus mRNA for interleukin-2
emb|X01664|MMIL02 Mouse interleukin-2 gene exon 3 sequence
gb|U41505IMMU41505 Mus musculus interleukin-2 (IL-2) mRNA, ...
gb|K02292|MUSIL2T Mouse interleukin-2 mRNA, complete cds. >...
gb|U41494IMMU41494 Mus musculus interleukin-2 (IL-2) mRNA, ...
embiX01772|MMIL04 Mouse mRNA for interleukin-2 (IL-2)
gb|U41506IMMU41506 Mus musculus interleukin-2 (IL-2) mRNA, ...
gb|U41504IMMU41504 Mus musculus interleukin-2 (IL-2) mRNA, ...
emb1X07422|ARMIL2 Artificial mouse mIL2 gene for interleukin 2
gb|M16761|MUSIL2A02 Mouse interleukin 2 (IL-2) gene, exon 3.
gb|AF065914.1|AF065914 Mus musculus strain C57BL/6J interle...
gb|U41495IMSU41495 Mus spretus interleukin-2 (IL-2) mRNA, m...

42
42
42
42
42
42
42
42
42
42
42
42
32

0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
1.3
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Fig. 22 IL-2 RT-PCR mRNA analysis. RNA was extracted
from H238 (H), pcH238 (P) and H238-IL2 (I) cells using the
TRI reagent as described. Single step RT-PCR and murine IL2 specific primers were used to amplify the RNA. Negative
control (-RT) and a kit control (K) were included. Distinct
amplification of the IL-2 message is observed from H238-IL2
cells in comparison to no amplification from the other cell
groups.
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RT-PCR was also used to amplify TGF-pi transcript from RNA obtained
from pcH238, H238 and masH238 cells. Using the single step procedure and a
pre-determined controlled number of amplification cycles, semi-quantitative
information was obtained on the relative amount of TGF-p transcripts between
the different cell lines. Levels of amplified TGF-p mRNA (236bp) appear to be
visibly reduced in total RNA from similar numbers of masH238 cells, in
comparison to levels obtained from H238 or pcH238 cells (Fig. 23). These results
are in agreement to protein expression levels quantified from cell culture
supernatants using ELISA (Fig. 19).
F. In vitro Growth Kinetics
To evaluate concerns that plasmid transfected H238 cells would behave
differently than wild type H238 cells in terms of their growth and morphogenic
properties, the kinetics of all these cells were measured using an MTS assay.
The procedure for this experiment has been described in detail. Individual
standard curves for the MTS assay were generated for each run of this
experiment for all the cell lines tested. A representation some of the curves from
an experiment is shown in Fig. 24. A linear correlation was plotted to calculate
cell number and optical densities. R-values for the standard curves obtained
ranged from 0.85 - 0.97 (Fig. 24). The closer the R value is to 1, the greater the
degree of correlation which can be interepreted.
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Fig. 23 TGF-(31 RT-PCR mRNA analysis. RNA was extracted
from H238 (H), pcH238 (P) and masH238 (M) cells using the
TRI reagent as described. Antisense efficiency was measured
by establishing the amount of TGF-p expression using TGF-pi
gene specific primers and 20 cycles of PCR, thus preventing
the plateau effect. The amplified band (236bp) from masH238
cells has a lesser intensity then those obtained from H238 and
pcFI238 cells. The difference in intensity was determined using
the Alpha Innotech Imager.
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Fig. 24 Representative Standard curves used for co
relating OD(490nm) and cell numbers for assays using the
MTS assay. A. pcH238, B. masH238, C. H238 and D. H238IL2. The cells were diluted serially and plated as described in
the materials and methods. The cell numbers were determined
using the MTS assay, and a liner regression line calculated for
each cell line. The standard curves obtained show very good
correlation (R) values between optical density and cell number,
confirming the assay to be a feasible alternative to 3H-TdR.
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The growth kinetics for each cell line was determined by using the MTS assay.
The conditions for optimum OD measurements were pre-determined from
standard curves. After plating equal numbers of cells in complete media, the
growth kinetics were measured every 24hrs using the optimized MTS assay. A
representation of multiple experiments is shown in Fig. 25. During the course of
this experiment, the cell lines showed similar growth patterns to the wild type
H238 cells. Microscopic examination of the cells showed that there were no
readily observable morphologic differences between any of the groups (data not
shown).
Previous work by Mao et al (1995), had shown that high doses of human
IL-2 could inhibit H238 growth. To determine if this effect would be observed with
murine IL-2, H238 cells were grown in vitro in complete medium supplemented
with different amounts of IL-2. H238 proliferation was measured by the MTS
assay, complete details of the experiment have been outlined above. There were
no measurable differences between the growth rates of H238 cells grown in
different concentration of murine IL-2 and control H238 cells grown in complete
normal media (Fig 26) over a 72 hr period. All the growth curves showed
overlapping standard deviations, therefore, showing no significant differences.
The experiment was stopped after 72hrs when the cells reached 100%
confluency. A similar experiment was designed to determine the effect of TGF-p
on H238 cells. Two groups of H238 cells were cultured in vitro with complete
media supplemented with different concentrations of TGF-p (10 - 0.3125ng/ml).
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Fig. 25 Growth kinetics of wild type and transformed cells.
Equal numbers of wild type and transformed cells were plated
in 96 well strip plates as described. Proliferation of these cells
was measured using the MTS assay, every 24 hrs. The
observed OD was translated to quantitative data from
concurrent standard curves for each respective cell population.
There was no statistically significant difference between the
growth kinetics of either wild type or any of the transfected cell
types.
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Fig. 26 Effect of exogenous murine IL-2 on H238 growth.
H238 cells were grown in media with different dilutions of
murine IL-2 to evaluate any modification of growth. Controls
without any added IL-2 were included as a comparison.
Proliferation of all the groups was measured using the MTS
assay over a period of 72 hrs as described in the materials and
methods. This figure shown that murine IL-2 present in the
media at biological concentrations does not modulate growth
of H238 cells.

127

c/)
c
03
</>
3
o
h-

600

"D

500
400 -

co
^
O
o
53

300 200 -

_Q

E

3

100 0
Contol
^-0.78

72 Hrs

48 Hrs

24 Hrs
■

6.25
0.39

128

+

3.12

1.56

0.19

0.09

One group had 600ng/ml of polyclonal anti-TGF-p antibody added to the media.
This served as a control for any growth modulatory effects of TGF-p. The growth
kinetics of the cells were monitored for 96hrs using the MTS assay. Interestingly,
from this experiment, TGF-p did not display any growth modulatory activity as all
the cells from both groups showed a similar rate of growth (Fig. 27).
G. In vivo Experiments
Having shown that the transfected H238-IL2 cells could express
biologically significant amounts of IL-2 and that TGF-p expression was
significantly reduced from masH238 cells, the anti-tumor efficacy of these
modalities was tested in immuonocompetent BALB/c mice. Prior to injecting the
different groups of BALB/c mice with wild type or transfected cells, the efficacy of
antisense suppression of TGF-p was measured again from masH238 cells by
quantifying TGF-p protein from conditioned media using an ELISA. There was a
significant decease (5 fold) in TGF-p expression observed from these cells. Wild
type and plasmid control H238 cells expressed approximately 470-500pg/ml of
TGF-p, whereas, masH238 cells expressed approximately 180pg/ml (p<0.05)
(Fig. 28).
Five hundred thousand H238, pcH238, masH238 and H238-IL2 cells were
injected s.c. into different groups of BALB/c mice. Tumor development was
allowed to progress and measurements initiated once palpable tumors formed.
The figure shown is representative of three different runs. Mice injected with
either wild H238 or plasmid control H238 cells had tumor volumes between 800-
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Fig. 27 H238 cell proliferation in response to TGF-p. H238
cells were grown in vitro in serum free media supplemented with
different dilutions (10 - 0.15625ng/ml) of TGF-p1 (A). An identical
experiment was set up simultaneously, but having media
supplanted with a 10 fold greater amount of antibody (600ng/ml)
to TGF-p1 (B). H238 cell proliferation was measured using the
MTS assay, as previously described. For clarity sake and as the
biological concentrations lie within 10ng/ml to 0.3125ng/ml, the
graph represents these concentrations. There were no significant
differences observed in the growth of H238 cells in response to
different amounts of exogenous TGF-p in the medium
corroborating the results of Uhm et al, 1993.
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96 h+s

Fig. 28 Pre-in vivo TGF-p Expression. H238, pcH238 and
masH238 cells were plated at a density of 5 x 105 cells/well.
An aliquot of media was collected every 24hrs and stored at 20°C. TGF-p expression was analyzed at 72hrs prior to
initiating in vivo experiments. TGF-p expression from
masH238 cells was significantly lower then expression from
the other groups. *Significantly lower (p<0.02) then the wild
type or pcH238 cells.
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masl-238

1000mm3. Mice injected with masH238 showed small tumor growth (approx.
300mm3), but were significantly different (p<0.05) from groups injected with wild
type and plasmid control cells. Tumor inhibition was greatest in mice injected with
H238-IL2 cells. Mice in this group formed very small tumors (<200mm3, p<0.05)
and most were tumor free (Fig. 29). The animals in this group did not show any
sign of toxicity, contrary to some reports where significant death of the animals
have been observed. The statistical significance of this experiment is shown in
Table 4, where the statistical significance of transfected cells is presented in
comparison to wild type H238 cells. Through the course of this experiment, both
wild type and control H238 injected animals displayed 80-100% tumor incidence
(p>0.1 - when compared to wild type H238 injected group). However, masH238
and H238-IL2 cells showed definite differences in tumor growth, which was
evident throughout the tumor measurement period. Statistical analysis between
non-tumor bearing groups (H238-IL2 and masH238 injected animals) in
comparison to wild type H238 injected animals showed a consistent p value of
<0.05, confirming the efficacy of using IL-2 and antisense TGF-p as anti H238
tumor agents.
H. Mitogen Stimulated Lymphoblastogenesis assay
To determine if the anti-tumor effect was due to involvement of an
immunological component, mitogen and flow cytometry analysis were performed.
Each new batch of mitogens was titrated, to obtain maximal spleen cell
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Fig. 29 Tumor volumes in BALB/c mice immunized with
wild type and transfected H238 cells. Mice were immunized
using the protocol out lined and in accordance with Loma
Linda Animal Care Regulations. Tumor measurements were
initiated once palpable tumors were observed. Mice were
sacrificed when the tumors severely handicapped the animals.
Mice injected with H238-IL2 and masH238 cells developed
significantly smaller tumors then wild type or control injected
animals.
(a) masH238 group significantly different from wild type H238
cells (b) H238-IL2 group significantly different from wild type
H238
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Table 4 Statistical significance (p values )of in vivo study.
Tumor volumes of all the mice were compared using the
Students T-test to tumors formed by wild type H238 cells.
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Day 1

Day 3

Day5

Day 7

Day 9

Day 11

H238

1.000

1.000

1.000

1.000

1.000

1.000

pcH238

0.174

0.484

0.350

0.271

0.346

0.122

masH238

0.053

0.015

0.017

0.000

0.004

0.000

H238-IL2

0.002

0.001

0.005

0.000

0.000

0.000
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proliferation. An example of such a titration is shown in Fig. 30. Briefly, the
mitogens were diluted and added to spleen cell cultures. Spleen cell proliferation
was measured using 3H-TdR uptake and the MTS assay. The stimulation index
was then calculated from these values. In this titration the dilutions that caused
maximal spleen cell proliferation were: PHA- 1:160, ConA- 1:320, P.W. - 1:20
and IPS-1:1280.
Mice from the in vivo experiment were euthanized and spleens harvested.
These were processed for the lymphoblastogenesis assay as described. Spleen
cells from mice injected with H238 and pcH238 cells (large tumor bearing mice)
showed significantly lower proliferation (p<0.05) in response to either PHA (H238
SI = 18± 12 and pcH238 SI =32 ± 11) and Con A (H238 SI = 18 ± 10, pcH238
SI = 29 ± 11). The SI values from small tumor bearing or tumor free mice were
significantly higher in response to both mitogens. Spleen cells from mice injected
with masH238 cells has SI values of 62 ± 9 in response to PHA and splenocytes
from H238-IL2 injected mice had SI values of 140 ± 23 (p<0.05) (Fig. 31). There
was no significant trend observed from spleen cells stimulated with IPS.
Splenocytes obtained from small/non tumor bearing mice did show a higher
proliferation then cells obtained from tumor bearing mice but the differences were
not statistically significant (p>0.05).
Spleen cell proliferation was also measured using the MTS assay (Fig.
32). The proliferation trend observed was comparable to 3H-TDR, but the
individual values were not statistically significant from each other. Spleen cells
from H238 and pcH238 injected mice had SI values of 0.122 ± 0.097 and 0.214 ±
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Fig. 30 Mitogen Titration. The titration was set up using the
procedure described in the Materials and Methods. Spleen
cell proliferation was measured using either the MTS assay (A)
or 3H-TdR (B). The dilution generating the highest SI value
was used in all further experiments. PHA - 1:160, Con A 1:320, PW-N/A, IPS-1:20
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Fig. 31 Mitogen stimulated spleen cell lymphoblastogenesis
assay. Spleens were harvested from the mice, processed into
erythrocyte free suspension as described and stimulated using
pre-titrated mitogens: Phytohemaglutanin(PHA), Concanavalin A
(ConA) and lipopolysaccharide (IPS). Proliferation was measured
by 3H-TDR uptake and the results expressed as Stimulation Index
(SI). Non-tumor bearing mice (masH238 and H238-IL2 groups)
show an increase in mitogen responsiveness (SI value) in
comparison to tumor bearing mice (H238 and pcH238 groups).
*Significantly different from tumor bearing groups.
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Fig. 32 Mitogen stimulated spleen cell lymphoblastogenesis
assay. Spleens were harvested from either H238, pcH238,
masH238 or H238-IL2 injected mice, processed in to erythrocyte
free suspension as described and stimulated using pre-titrated
mitogens: Phytohemaglutanin(PHA), Concanavalin A (ConA) and
lipopolysaccharide (IPS). Proliferation was measured by the MTS
assay and the results expressed as Stimulation Index (SI). The
results obtained show a very similar trend to an identical
experiment described, but assayed using 3H-TDR, however, there
was large variations between individual samples assayed.
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0.151 in response to PHA. Mice injected with masH238 and H238-IL2 cells had
SI values of 0.308 ± 0.114 and 0.431 ± 0.145, respectively.
I. Flow Cytometry Analysis
To dissect the immune response further, splenocytes and peripheral blood
were stained with different cocktails of fluorescent-labeled antibodies and
analyzed using flow cytometry. Fig 33, 34
J. TGF-p Receptor Analysis
Based on previous results (Uhm et al, 1993), H238 cells are non
responsive to TGF-p. To determine the mechanism for this behavior, the
expression of functional TGF-p receptors on H238 cells was studied. Using RTPCR under stringent conditions and very specific primers, mRNA expression of
both the receptors were evaluated. Details on the experimental conditions have
been described and also have been listed in Table 2. All RT-PCR amplified
products were purified and submitted for sequencing at the Core Sequencing
Facility at Loma Linda University. The sequences were then aligned to published
sequences in GenBank using BLAST to confirm their identity.
The first set of primers used to amplify Type Type II receptors and I were
published by Amoroso et al, (1998). The primers amplified a 761 bp product of
TGF-pRI and a 961 bp product of TGF-pR2. These were resolved on a 1%
agarose gel as shown in Fig. 35. To further verify the expression of both
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Fig. 33 Immune activation via CD71 protein expression.
This lymphocyte population was determined by labeling the
cells (A - Spleen cells, B - peripheral blood) with an antibody
cocktail, described in the material and methods. Fluorescent
cells were sorted and quantified using the FACSCalibur and
the data analyzed on CellQuest software. Each column
represents the mean +/- standard deviation.
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Fig.34 Immunephenotyping splenocytes. This lymphocyt
population was determined by labeling the cells with a
antibody cocktail, described in the material and methods
Fluorescent cells were sorted and quantified using th
FACSCalibur and the data analyzed on CellQuest software
Each column represents the mean +/- standard deviation.
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Fig. 35 TGF-pR1 and TGF-pR2 mRNA analysis. RNA was
extracted from H238 using the TRI reagent as described.
Messenger RNA for both receptors was analyzed using RTPCR with gene specific primers shown in B. Amplified RT-PCR
products (TGF-pRI - 761 bp, TGF-pR2 - 961 bp) were excised,
purified and sequenced with the same primers. Sequencing
results indicate that the products were identical to published
receptor sequences.
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receptors, a second set of primers published by Lowsky et al, 2000 was used.
These primers amplified a 217bp fragment of TGF-(3R1 and a 287bp of TGF-pR2
(Fig. 36), which corresponded perfectly to the published R1 and R2 results.
Again, both amplified products were purified and submitted for sequencing at the
Core Sequencing Facility at Loma Linda University. The sequences were then
aligned to published sequences in GenBank using BLAST to confirm their
identity, as before.
TGF-pRI was also analyzed in another experiment where primer sets from
both sources were used. The results are shown in Fig. 37. Two bands were
observed which correspond to the two amplified regions of TGF-pRI, 217bp and
761 bp as shown in Fig 37.
Using the primers from Lowsky et al (2000), total RNA from H238 cells
was amplified again in an additional experiment. In addition, PCR reactions were
set up using plasmids with cDNA’s for TGF-pR1 (XF-144) and TGF-pR2 (XF-122)
and Lowsky’s (2000) primers. The amplified products were resolved on a 1%
agarose gel. RT-PCR reactions and PCR reactions using primers for the Type I
receptor resulted in bands of 217bp for both reactions. The next reaction set up
used primers for TGF-pR2 to amplify a band of 287bp from both RT-PCR and
PCR reactions (Fig. 38). These results show expression of mRNA for both Type I
and Type II TGF-p receptors.
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Fig. 36 TGF-pR1 and TGF-pR2 mRNA analysis. RNA was
extracted from H238 using the TRI reagent as described.
Messenger RNA for both receptors was analyzed using RTPCR with gene specific primers shown in B. Amplified RT-PCR
products (TGF-pR1 - 287bp, TGF-pR2 - 217bp) were excised,
purified and sequenced with the same primers. Sequencing
results indicate that the products were identical to published
receptor sequences.
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Fig. 37 RT-PCR analysis of TGF-pR1. Total RNA was extracted
as described and amplified using 2 different sets of primers
specific to TGF-pR1. The primers have been described in detail
Table 3. The RT-PCR protocol utilized was similar to the one
outlined in the material and methods section. Amplified products
were gel purified and sequenced to confirm their identity. The
sequences obtained show perfect identity with published
sequences for TGF-pR1.
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Fig. 38 TGF-pR1 and TGF-PR2 mRNA analysis (A) and
primers used (B). RNA was extracted from H238 using the
TRIzol reagent as described. Messenger RNA for both receptors
was analyzed using RT-PCR with gene specific primers shown in
B with either total RNA samples from H238 cells (1,2) or TGFpR1 or TGF-pR2 cDNA’s (I, II). Amplified RT-PCR products (TGFpR1 - 217bp, TGF-pR2 - 287bp) were excised, purified and
sequenced with the same primers. Agarose gel analysis show
that the amplified products from FI238 RNA samples for either
TGF-pR1 orTGF-pR2 are equal sizes with the positive controls.
Negative controls (a, b) were set up concurrently without MMLV
reverse transcriptase enzyme to control for genomic DNA.
Sequencing results indicate that the amplified products were
identical to published receptor sequences.
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1000 bp

500 bp

Primers Set 1 (Lowsky, 2000)
1 - H238 + TGF-PR1 '
1 - XF-144 + TGF-PR1
2 - H238 + TGF-PR2
II -XF-122 + TGF-PR2
a - H238 RNA + TGF-PR1 - RT
b - H238 RNA + TGF-PR2 - RT
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K. Immunocytochemistry and Laser Scanning Microscopy
Having shown expression of the mRNA transcripts for both Type I and
Type II receptors, immunocytochemistry (ICC) was employed to evaluate
expression of TGF-p receptors on the cell surface. Using a polyclonal primary
antibody specific to either Type I or the Type II receptor and a FITC labeled
secondary antibody, H238 cells were stained in 2-well chambered slides as
described. PI was used to counterstain the nuclei, to allow visual differentiation of
the cells. Controls used included, PBS and non-immune rabbit sera (NIRS) (Fig.
39A). Cells stained using either of these two controls did not exhibit any
significant cellular staining, apart from background. Cells stained with the
antibody specific for Type I receptor (Fig. 39B) showed a distinct green staining
pattern, whereas, cells stained with antibody specific to Type II receptor
displayed a greenish hew. This was pre-dominant in the cytosolic region of the
cells (Fig. 39C). This was thought to be due to sequestering of the protein in the
cell, preventing insertion in the membrane (Koli and Arteaga, 1997). The Type II
receptor was further examined using specific primers (Table 2); S1, S2 and S3,
which amplified specific regions by RT-PCR. These primers amplified a 483bp,
496bp and a 485bp respectively (Fig. 40). The reaction conditions used have
been described and further details can also be found in Table 3. These products
were sequenced and found to be identical to published receptor sequences
found in GenBank.
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Fig. 39 Immunocytochemistry of H238 cells. The cells
were plated onto 2-well divided slides. A two-step staining
procedure was used, with the cells washed thoroughly
between each step. Receptors present were stained green
(FITC), whereas, nuclei were stained red (propidium iodide).
These cells were analyzed using a microscope based laser
scanning cytometer. H238 stained with A. Non immune rabbit
sera B. TGF-(3R1 antibody and C. TGF-pR2 antibody.
CT)
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Fig. 40 RT-PCR analysis of TGF-pR2. Total RNA from H238
cells was amplified using primers obtained from Lowsky et
a/.(2000). These primers amplified different sections of the
TR2 mRNA. Primer S1 was expected to generate a 483b
fragment, primer S2 generated a 461 bp and primer S3
generated a 485bp product. Amplified products were purified
and extracted from agarose gels and submitted for
sequencing. The sequences were then compared to published
sequences using BLAST.
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L. Laser Scanning Cytometry
H238 cells stained using either TGF-pRI, TGF-pRII or non-immune rabbit
sera and PBS as negative controls. The cells were observed using a microscope
based multiparameter laser scanning cytometer (Compucyte Corp, Cambridge,
MA) interfaced with a PC based Wincyte™ software as described in the Materials
and Methods. Cells stained with TGF-pR1 showed FITC staining in 15.2% (Fig.
41B) population of the cells, whereas, cells stained with TGF-PR2 showed FITC
staining in 7.2% (Fig. 42B) of the population. Cells stained with either PBS or
non-immune rabbit sera demonstrated background FITC staining of 0.2% (Fig.
43).
M. Western Blot Analysis
H238 cells were lysed in lysis buffer and immunoprecipitated (IP) using
either TGF-pR1 orTGF-pR2 anti-bodies. The immunoprecipitated product was
then electrophoresed on a SDS-PAGE gel, transferred onto nitrocellulose and
probed with either anti TGF-pRI or anti TGF-PR2 antibody as described. The
molecular weight of bands was calculated using the Alpha Innotec Imager.
Whole cell lysate from H238 and mink lung epithelial cells (C64-positive control)
probed with TGF-pR1 showed a 53kDa band corresponding to the molecular
weight size of TGF-pR1 (Fig. 44). To confirm the presence of Type 2 TGF-p
receptor, whole cell lysate from H238 and L6 cells was electrophoresed and
probed on an immunoblot using antibody specific to TGF-(3R2. A band
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Fig. 41 Histogram (A) and dot blot (B) of fluorescence
intensity of H238 cells stained with TGF-pRI. H238 cells
were cultured on a 2-well slide and stained using a primary
antibody specific to TGF-pRI and labeled using a secondary
conjugated to FITC. The nuclei were stained with propidium
iodide solution. Identical contouring and PMT (photomultiplier
tube) gain values were used in a single experiment to assure
equivalence of fluorescence intensity units. In this
representation, the population of H238 cells shown to express
the TGF-pRI is shown by the green part of the histogram and
the green dots on the dot plot. Approximately 15.2% of the
cells are expressing the receptor on the surface.
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Fig. 42 Histogram (A) and dot blot (B) of fluorescence
intensity of H238 cells stained with TGF-pR2. H238 cells
were cultured on a 2-well slide and stained using a primary
antibody specific to TGF-pR2 and labeled using a secondary
FITC conjugate. The nuclei were stained with propidium
iodide. Identical contouring and PMT (photomultiplier tube)
gain values were used in a single experiment to assure
equivalence of fluorescence intensity units. In this
representation, the population of H238 cells shown to express
the TGF-pR2 is shown by the green part of the histogram and
the green dots on the dot plot. Approximately 7.2% of the cells
are expressing the receptor on the surface.
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Fig. 43 Representative Histogram (A) and dot blot (B)
of fluorescence intensity of H238 cells stained with preimmune rabbit sera. H238 cells were cultured on a 2-well
slide and stained using pre-immunized rabbit sera and
labeled using a secondary conjugated to FITC. The nuclei
were stained with propidium iodide. Identical contouring and
PMT (photomultiplier tube) gain values were used in a
single experiment to assure equivalence of fluorescence
intensity units. In this representation, the population of H238
cells showed no staining, thus, controlling for any
background staining with either Type 1 or Type 2 receptors
antibody.
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Fig. 44 TGF-pR1 protein expression from H238 whole cell
lysate. H238 cells were lysed and protein concentration
measured using the modified Bradford assay. TGF-pR1 was
immunoprecipitated (IP) overnight and harvested using protein
A sepharose beads. The precipitate was electrophresed on a
SDS-Tricine gel and probed with anti-TGF(3R1. Mink lung
epithelial cell (CL-64) lysate was used a positive and L6 cell
lysate used as a negative control. The western blot was
developed using an enhanced chemiluminescent technique as
described. A band of approx 53kDa was obtained confirming
expression of TGF~pR1 protein from whole cell lysate of H238
and CCL-64 cells. L6 cells showed a distinct reduction in the
proportion of TGF~pR1.
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corresponding to approximately 65.7kDa was obtained which was equivalent to
the size of the Type 2 TGF-pR (Fig. 45).
To resolve the localization of the proteins within the H238 cells, whole cell
lysate was fractionated into both membrane and cytosolic fractions. Positive
controls were included in all the experiments with lysate from L6 cells served as
positive controls for TGF-(3R2 and lysate from CCL-64 cells was used to control
for TGF-pR1 expression. The cytosolic and membrane fractions of H238 cells
and L6 cells was probed for TGF-pR2 using antibody specific to the type 2 TGF-p
receptor (Fig.46). The developed blot showed that the type 2 receptor was being
expressed in both fractions of either cell line. It was interesting to observe that
the level of expression was quite different between both cell lines, even though
equivalent amounts of protein were loaded onto the gel. L6 cells showed a
higher level of expression of the type 2 receptor from both fractions in
comparison to levels observed from H238 cells.
Expression of the type 1 receptor was evaluated using the same
procedure (Fig. 47). However, the positive control was obtained from the lysate
of mink lung epithelial cells. The immunoblot revealed that H238 cells do indeed
express the typel receptor. Again, there was an obvious difference in expression
levels between the control (CCL-64 lysate) and H238 lysate, even though
equivalent amounts of protein were loaded.
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Fig. 45 TGF-pR2 protein expression from H238 whole cell
lysate. H238 cells were lysed and protein concentration
measured using the modified Bradford assay. TGF-pR2 was
immunoprecipitated (IP) overnight and harvested using protein
A sepharose beads. The precipitate was electrophresed on a
SDS-Tricine gel and probed with anti~TGFpR2.16 cell lysate
was used a positive control. The western blot was developed
using an enhanced chemiluminescent technique as described
in the materials and methods. A band of approx 75kDa was
obtained in both lanes confirming the expression of TGF-PR2
protein from whole cell lysate of FI238 cells.
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Fig. 46 TGF-pR2 protein expression from membrane and
cytosolic fractions of H238 and L6 cell lysate. H238 cells
were lysed and separated into the different fractions as
described. TGF-|3R2 was immunoprecipitated (IP) overnight
and harvested using protein A sepharose beads. L6 cells were
used as a positive control and prepared in the same manner. A
band of approx 75kDa was obtained in all the lanes confirming
the expression of TGF-(3R2 protein from both membrane and
cytosolic fractions of both cell lines. It was, however,
interesting to note that the density of the bands obtained from
L6 cells was greater then from H238 cells, probably indicating
differences in the expression levels of the receptor.
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Fig. 47 TGF-pR1 protein expression from membrane and
cytosolic fractions of H238 and CCL-64 cell lysate. H238
cells were lysed and separated into the different fractions as
described. TGF-pR1 was immunoprecipitated (IP) overnight
and harvested using protein A sepharose beads. CCL-64 cells
were used as a positive control and prepared in the same
manner. A band of approx 65kDa was obtained in all the lanes
confirming the expression of TGF-pR1 protein from both
membrane and cytosolic fractions of both cell lines.
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N. Effect of Radiation on H238 cells proliferation
The propensity of wild type H238 and IL-2 transfected H238 cells to
respond to gamma radiation was evaluated by measuring proliferation under
variable doses. The results obtained from using either MTS or 3H-TdR to
measure proliferation proved to be interesting. Proliferation results obtained from
utilizing the MTS assay showed that with all the different doses of radiation
tested, there was no difference in the growth of these cells in comparison to the
un-irradiated controls. This held true for both H238 and IL-2 transfected cells.
The cells appeared to proliferate exponentially without any change in the kinetics.
This experiment was repeated up to 3 times and, the results obtained were
comparable - indicating that the H238 cell line and its derivatives were NOT
susceptible to lethal doses of radiation over a period of 96 hrs (Fig. 48).
To confirm and verify these results, this experiment was repeated but
proliferation was measured using the traditional 3H-TdR uptake method. The
results obtained are shown in Fig. 49. Cell irradiated with 5Gy or 10Gy showed a
decrease in proliferation after 48 hrs, where the un-radiated cells continued to
show normal proliferation until they monolayered.

181

Fig. 48 Effect of Radiation Dosage on H238 and H238-IL2
cells. H238 and H238-IL2 cells were plated in 96 well strip well
plates and irradiated as described in the Methods section. Cell
proliferation was measured using the MTS assay. The results
obtained from this experiment show that the H238 cell line and
its transfected derivatives are resistant to lethal doses of
gamma irradiation. Cells subjected to these doses appeared to
proliferate at a similar rate in comparison to the un-irradiated
control cells. These results seem very abnormal because
murine cell lines have never been shown to have radiation
resistant genes like the Deinococcus radiodurans.
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Fig. 49 Effect of Radiation Dosage on H238 and H238-IL2
cells. H238 and H238-IL2 cells were plated in 96 well strip well
plates and irradiated as described in the Methods section. Cell
proliferation was measured using the 3H-TdR assay. The
results obtained from this experiment show that the H238 cell
line and its transfected derivatives are susceptible to lethal
doses of gamma irradiation (>10G). Cells subjected to these
doses had a sharp decline in proliferation in comparison to the
un-irradiated control cells. These results are supportive of
previous results obtained by other investigators.
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DISCUSSION
Transforming growth factor-p (TGF-p) is a member of a super-family of
growth factors which play important roles in the regulation of various physiologic
processes (Kingsley, 1994). The immediate family of TGF-p consists of five
isoforms of which types 1 to 3 are found in mammals. These TGF-p isoforms are
homologous 25 kDa disulfide-linked dimers (Alevizopoulos and Mermod, 1997).
TGF-pi is the only isoform known to circulate in plasma and the one most rapidly
induced in response to a variety of environmental stimuli. The three isoforms are
interchangeable in most biological assays, but are distinct in their tissue
specificity (Roberts et al., 1991). TGF-p is produced by a variety of normal cells.
Platelets, osteoblasts and other bone cells are the major sources of TGF-p, but
activated lymphocytes, macrophages and neutrophils also secrete TGF-p
(Assoian et al., 1987). Furthermore, tumors and tumor cell lines are known to
produce TGF-p (Blanckaert etal., 1993; Picon et al., 1998; Wikstrom et al.
1998). TGF-p exerts growth inhibiton activity on most cells. Under certain
circumstances, cells can be stimulated by TGF-p, depending on type,
differentiation and activation state. TGF-p appears to play a role in several
pathophysiologic processes, including malignant cell growth.
TGF-p has pleiotropic and profound effects on the immune system. It is
the most potent immunosuppressor described to date (Letterio, 2000), yet TGF-p
plays an essential role in maintaining normal immune function. The phenotype of
TGF-p1 knock-out mice clearly supports an essential role for TGF-p in the
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maintenance of immune system homeostasis. These knock-out mice exhibit
severe immune dysregulation leading to death around day 30. The mice develop
multifocal infiltration of inflammatory cells in many organs and increased
numbers of proliferating cells can be found in the lymphoid tissue (Christ et al.,
1994; Shull et al., 1992).
Other studies also support the important role of TGF-p in the maintenance
of immunologic homeostasis. It has been shown that in vitro activation of resting
T and B cells results in an increase in the expression of TGF-p receptors and in
an increase in TGF-p mRNA, resulting in a self limitation of lymphocyte clonal
expansion (Kehrl et al., 1986). This indicates that TGF-p may act as an
auto regulatory lymphokine and may, therefore, be an important signal in the
regulation of inflammation.
To understand and explore this multifunctional cytokine, this dissertation
work was based on two primary aims. The first aim focused on the development
and pre-clinical trials of a gene therapy approach to render the H238 tumor more
immunogenic. This approach focused on the use of an antisense TGF-p plasmid
construct to reduce TGF-p expression. In addition, FI238 tumor cells were also
engineered to express IL-2 to evaluate the restoration of normal immune
competence, including anti-tumor activity, and toxicity effects of using this
potential immunotherapeutic modality. The second aim of this project
investigated the inert responsiveness of H238 cells to the modulatory effects of
TGF-p. This component of the investigation focused primarily on expression of
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complete mRNA transcripts of both the types I and II receptors. Receptor protein
expression and localization was also investigated.
Our initial experiments were conducted to confirm the immunogenicity of
the H238 tumor. When BALB/c mice were challenged with varying numbers of
H238 cells, lower inocula (1000 to 100,000 cells) did not cause any apparent
tumor formation. In comparison, inocula of equal to or greater than 5 x105 H238
cells caused the formation of large fibrosarcomas. This suggests that the H238
tumor model exhibits an inherent amount of immunoreactivity, possibly due to the
expression of specific kinds of tumor-associated antigens. The growth of the
tumor recognized by the immune system would be expected to be modulated
more readily by agents that enhance host responsiveness than the growth of a
non-immunogenic tumor. Previous work done by Stagg R (1988), showed that in
addition to TGF-p, H238 cells also expressed PDGF and FGF. This report
extends this finding by showing that in addition to TGF~pi, the H238
fibrosarcoma expresses the type 2 and type 3 isoforms of TGF-p. This is
significant since various models have been described by different investigators,
who have shown that fibrosarcomas are able to express this potent
immunosuppressive cytokine and its isforms. These can be found both in murine
and human neoplasias and, in addition, some groups have demonstrated that
multiple isoforms of TGF-p can be expressed from various cancerous tissues.
Chakravathy et al (1999) and MacCAIIum ef a/(1994) have shown that neoplastic
human breast cancer expresses all three isoforms of TGF-p. In addition, they
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demonstrate that these tumors expressed primarily TGF~(31 and 3. Expression of
all three isoforms has been further confirmed in multinodular goiters,
differentiated thyroid carcinomas (Kimura et al., 1999) and glioblastoma cells
(Constam et al., 1992). Additionally, testicular cancer (Cardillo et al., 1998),
disseminated malignant melanoma (Krasagakis et al., 1998), and human ovarian
tumors (Bartlett et al., 1997) have shown verifiable expression. Expression of
TGF-p from all these carcinomas validates the need for further exploratory
procedures to identify mechanisms and to determine the potential modalities for
controlling TGF-p expression.
It has been demonstrated that the three TGF-p isoforms have specific
biological activities (Foitzik et al., 1999; 2000). These authors addressed the
question of whether the three different isoforms gave rise to specific signals. As a
model system, they used hair follicle development and demonstrated that TGFp2 was an inducer of murine hair follicle morphogenesis. On the other hand,
TGF-p1 had an inhibitory effect, whereas TGF-p3 did not seem to affect any
aspect of the development. The 3 isoforms also appeared to have common
effects that may have reflected the biological effects of ancestral TGF-p. They
hypothesized that during the development of these isoforms, which probably took
place before the avian evolution, additional new biological needs probably arose.
Thus, each isoform had both specific and common effects on the development of
follicles. In vivo, the temporal and spatial synthesis of the 3 TGF-p isoforms was
strictly regulated, as illustrated by the differential expression during
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embryogenesis (Schmid etai, 1991) and wound healing (Frank et al., 1996). The
expression pattern of these isoforms could have been based on the overall
balance effect of TGF-p on the tumor cells themselves and on the surrounding
tissues and immune cells (Massague, 1998).
The primary reason why TGF-p has been drawn to the attention of various
investigators has been it’s potent immunosuppressive ability. TGF-p1 expressing
C3-FI derived UV induced fibrosarcomas, expressed MHC I and tumor specific
antigens but could not stimulate CTL’s in vitro and in vivo (Torre-Amione et al.,
1990). Suppressor macrophage capability also appeared to be increased in a
study using the murine fibrosarcoma cell line Meth-KDE (Alieva et al., 1995).
However, the immunosuppressive characteristic of TGF-p should not be limited
to itself. Several studies have shown that IL-10 (Murata et al., 2000) is a
compelling candidate to share the immunosuppressive potency title.
Other mechanisms by which production of TGF-p by tumor cells can
augment tumor growth are through the promotion of angiogenesis, resulting in an
increased blood supply to the tumor cells (Ueki et al., 1992), promoting of
metastasis and the formation of connective tissue (Haralson, 1997).
Since TGF-p is such a powerful immunosuppressive factor, the application
of immunotherapeutic approaches may be enhanced by the development of antiTGF-p strategies. By neutralizing TGF-p, not only the immunosuppression, but
also the tumor growth promoting activities of TGF-p may be prevented. This
includes enhanced angiogenesis (Fuhrmann-Benzakein et al., 2000), tumor
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stroma formation (Shanker et al., 1999) and increased metastasis. The first step
in minimizing the TGF-p induced effects would be surgical resection of the tumor
to remove the primary TGF-p source. However, this is not always possible, as
the localization of the tumor (eg brain tumors or systemic tumors, such as
leukemia) or the presence of multiple metastases may make it essentially
impossible to perform such surgical excision procedures.
Another way to neutralize TGF-p would be by using cytokine scavengers.
One of the identified TGF-p scavengers is a2~macro-globulin (o^M). Alpha 2M is
a glycoprotein present in high concentrations in human plasma. Two forms of
a2M have been identified: a native form and an activated form (Gonias and
Rizzo, 1983). Both forms have the capacity to bind cytokines, but TGF-p binds
preferentially to the activated form. The activated aaM-cytokine complexes are
rapidly removed from the circulation by a2M-specific receptor-mediated
hepatocyte endocytosis. Administration of activated a2M or augmenting the
clearance of the TGF-p-ot2M complex might be strategies for decreasing TGF-p
levels. However, side effects need to be taken into consideration. Not only TGFp, but also many other cytokines such as TNF-a and IL-6 bind to a2M (LaMarre
et al., 1991). The potential adverse effect of neutralizing these other cytokines is
still under investigation.
The strategy that we adopted to reduce TGF-p expression in the H238
tumor model was to use an antisense plasmid with the intent of increasing the
immunogenicity of this lethal fibrosarcoma by decreasing its immunosuppressiion
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potential. The aim of the antisense strategy is simply to down-regulate the
expression of disease-causing proteins by inhibiting gene expression at the level
of mRNA. The antisense strategy, at least in principle, allows for the rational
design of highly sequence- specific nucleic acid drugs that can target and even
destroy a given mRNA. The fidelity of antisense molecules, which are short
sequences of DNA or RNA, arises from their ability to Watson-Crick hydrogen
bond to their target mRNA within hybridization-accessible sites. Antisense
oligodeoxynucleotides duplexed with the target mRNA can inhibit gene
expression by several putative mechanisms, including translation arrest,
mediated by blockade of ribosomal read-through, and hydrolysis of mRNA by
recruitment of RNAseH.
Approaches based on the inhibition of TGF-p production by introduction of
TGF-p antisense have been proven successful in vitro as well as in vivo\
however, several hurdles exist. Unmodified phosphodiester backbone
oligonucleotides and unmodified ribozymes are rapidly degraded in biological
fluids (Fludson et al., 1999) by a combination of both endo- and exonucleases.
To overcome this problem, a variety of chemically modified oligonucleotides have
been enveloped (Kashihara et al., 1998). The most widely studied of these are
the phosphorothioate(PS) oligonucleotides where one of the non-bridging
oxygens in the phophodiester backbone is replaced with sulfur. More recently,
other modifications, such as peptide nucleic acids (Flamilton et al., 1999), 29methoxyethyl- (Khatsenko et al., 2000) and morpholino-based oligonucleotides
(Arora et al., 2000), have also been investigated.
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One of the major limitations for the therapeutic use of antisenseoligonucleotides and ribozymes is the problem of delivery mechanism. Import
into cells can be accomplished by exogenous delivery in which presynthesized
oligonucleotides come in direct contact with the plasma membrane, resulting in
subsequent cellular uptake (Lewis et al., 1998). Naked oligonucleotides are
poorly incorporated into cells in this fashion and often require a vehicle for
efficient delivery. In tissue culture, many classes of compounds have been used
as delivery vehicles including cationic liposomes, cationic porphyrins, fusogenic
peptides, and artificial virosomes (reviewed in Spiller et al., 1998a and Spiller et
al., 1998b). A substantial degree of protection from nuclease degradation is
conferred to the oligonucleotide when associated with such delivery vehicles.
Presently, some success has been achieved in laboratory tissue culture, but
efficient delivery for in vivo animal studies remains questionable (Jen and
Gewirtz, 2000). After evaluating some of the problems associated with delivery,
expression and stability of the antisense construct, we designed our antisense
strategy to use a plasmid vector under a strong CMV promoter and additionally
having integration sequences with a selection marker. We used a new
transfection reagent, which was activated-dendrimer molecules, that provided an
efficient delivery vehicle into the cell. A combination of these factors allowed
greater stability of the plasmid within the cell, and in addition, strong constitutive
expression of the antisense transcript was expected and observed.
We have successfully used an antisense modality to modify and abrogate
H238 tumorigenesis. Our technique utilized an antisense TGF-pi probe cloned

193

into the plasmid expression vector. This vector was transferred into H238 cells
using liposome-mediated transfection. Our in vitro results shown in fig. 19 and
23, clearly showed a 4-5 fold decrease in TGF-pi protein expression. Reduction
of TGF~pi mRNA was confirmed by RT-PCR analysis (fig 23). In vitro stable
transfection of a highly tumorigenic and invasive colon carcinoma cell line with a
TGF-p antisense expressing plasmid led to a five-fold reduction in TGF-p1
mRNA and a 15 fold reduction in TGF-p1 protein expression (Wu etal., 1992).
Fluang et al (1995), used a similar technique to investigate whether TGF-p was
an autocrine positive regulator of colon carcinoma. Using an antisense TGF-p1
plasmid under the control of the Rous-sarcoma virus promoter, TGF-p1
expression levels in the U9A cell line was reduced between 33-39% (Fluang et

al., 1995).
Loss of a plasmid can occur, however, resulting in outgrowth of TGF-p
secreting tumor cells (Fluang et al., 1995). Also, after antisense expression, the
TGF-p mRNA level increased again, indicating that the half-life of the antisense
appeared to be very short. The factors mentioned appeared to play an important
part in determining the efficiency and efficacy of our technique. Under the
limitations at hand, successful reduction in TGF-p was still observed in H238
cells transfected with the antisense plasmid.
BALB/c mice injected with a tumor bearing load of antisense transformed
FI238 cells showed significant tumor abrogation (p<0.001 tumor free animals) in
comparison to wild type and control groups (fig 29). In similar experiments by
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Fakhrai et al (1996), murine 9L glioblastoma cells were transfected with an
antisense TGF-(32 construct in vitro. Subcutaneous immunizations of tumor
bearing animals with antisense-engineered 9L cells resulted in a significantly
higher number of animals surviving for 12 weeks (100%) compared to
immunizations with control vector-modified 9L cells (13%). In the murine ovarian
teratoma (MOT) model, however, antisense transfected cells failed to decrease
tumorigenesis. Subcutaneous immunization of C3H mice with either a mixture of
IL-2 gene modified fibroblasts and unmodified murine ovarian teratoma MOT
cells [17% tumor-free animals] orTGF-p antisense-modified MOT cells alone
(0% tumor free animals) failed to induce significant protection compared with
immunization with unmodified MOT cells (Dorigo et al., 1998). Subcutaneous
immunization of C3H mice with a mixture of IL-2 gene transduced fibroblasts and
TGF-p antisense-modified MOT cells induced significantly better protection
against a subsequent intra-peritoneal tumor challenge compared with
immunization with unmodified MOT cells alone [69% vs 19% tumor-free animals,
P < 0.01] (Dorigo etal., 1998). In addition, repeated pre-clinical data provides
convincing evidence that for complete successful antisense therapy, the modality
needs to be used in combination with additional immunotherapeutic approaches.
Recent data from a phase II clinical trial with a phosphorothioate ODN
targeting c-raf-1 (ISIS 5132) in cancer patients showed that intravenous.
administration of the naked ODN resulted in a significant reduction in c-raf-1
mRNA levels in 13 of 14 patients as measured by semi-quantitative reverse
transcription assay (O'Dwyer et al., 1999). This data provides convincing
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evidence of an antisense mechanism of action for this ODN and represent the
first demonstration of a target mRNA knockdown in humans using an antisense
drug. However, the specificity of action needs to be further studied to ensure that
no other genes are affected.
The hypothesis that secretion of TGF-p by tumor cells is indeed an escape
mechanism from immunosurveillance is supported by the observation that
transfection of highly immunogenic tumors with TGF-p cDNA renders them less
immunogenic and, therefore, less inhibited in their growth (Torre-Amione et al.,
1990). In vitro stimulation of spleen cells with a highly immunogenic tumor cell
line transfected with TGF-p cDNA did not elicit CTL responses, indicating a role
of TGF-p in tumor-induced immune suppression. It has been shown that
production of IFN-y and TNF-a, both potent immunostimulatory cytokines, is
inhibited by incubation of T cells with TGF-p in vitro (Espevik et al., 1987).
Additionally, TGF-p inhibits T cell proliferation by down-regulating IL-2 and IL-2
receptor mediated proliferative signals. Examples of these activities by TGF-p
are inhibition of the IL-2 dependent phosphorylation of the retinoblastoma protein
and down-regulation of IL-2-mediated tyrosine phosphorylation of other proteins
(Ahuja et al., 1993). In the presence of TGF-p, an IL-2 dependent T cell line
started to accumulate in the G0/G1 phase of the cell cycle rather than initiating
proliferation upon IL-2 stimulation (Stoeck et al., 1989). Conversely, addition of
IL-2 to TGF-p treated mixed lymphocyte tumor cultures (MLTC) largely restored
the CTL activity (Inge et al., 1992).
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Immunosuppression has often been observed in cancer patients. TGF-p
plasma levels and levels of TGF-p production by the tumor in patients with
cancer often correlate with disease progression (Torre-Amione et al., 1990). It
also has to be considered that tumor-induced immunosuppression is not always
caused by TGF-p. Other immunosuppressive factors such as IL-10 (WojtowiczPraga, 1997) and direct tumor cell ~ T cell contact (Huber et al., 1992) can
suppress anti-tumor activity. In addition, down-regulation of MHC class I, antigen
expression, lack of co-stimulators and other factors impairing T cell activity may
facilitate the immune escape of the tumor. Patients undergoing immunotherapy,
injection of IFN-a, experienced an increase of TGF-p mRNA and subsequent
administration of IL-2 diminished the TGF-p mRNA to normal levels (Jahn et al..
1994). Results obtained in some of our pre-clinical murine studies utilizing IL-2
transfected H238 tumor cells provide support for the above data.
H238 cells were stably transfected with a plasmid expressing murine IL-2.
H238 cells showed high expression (600 - 1400pg/ml) of biologically significant
amounts of IL-2. There were no measurable signs of toxicity, morphological
differences or growth impairment between the stable plasmid transfected cells
and wild type H238 cells. Previous reports published by Mao et al (1995),
showed that H238 cell growth was inhibited in the presence of human IL-2. In
their study H238 cell proliferation was measured using 3H-TdR uptake in the
presence of human IL-2 (4 x 104 - 1 x 106 iu/well). The results obtained in our
study appeared to contradict these earlier observations. This could be attributed
to the lower physiological concentration of IL-2 used in our experiments. In

197

addition, the IL-2 used in the Mao at al’s (1995) study was human IL-2, whereas
our experimental procedure used murine IL-2. This may also have played a part
in some the differences in the data obtained, however, no concrete evidence has
been shown to substantiate this. Follow up experiments to investigate the
presence of functional IL-2 receptors on the H238 cells, would shed more light on
this mystery. The presence of IL-2 receptors and direct IL-2 induced growth
inhibition was previously noted with non-lymphoid cells, including human
squamous cell carcinomas (Weidmann eta!., 1992), newborn fibroblasts (Carloni
et al., 1989), and breast cancer cells (Paciotti and Tamarkin, 1988).
Additionally, the potential of cellular toxicity plays a significant role when
large amounts of IL-2 are used as reported by other investigators (Motzer et al.,
2000). The dose-limiting toxicities of high-dose IL-2 administration were reported
in both animal and human studies, thus hampering its wider use as a single
modality in cancer therapy (Tartour et al., 2000). IL-2 toxicity is manifested by a
vascular leak syndrome during and following the elicitation of lymphoid cell
proliferation and activation of LAK cell activity in situ (Zhang et al., 1999).
Modofied interleukin-2 (recombinant methionyl human interleukin-2) was
administered intralymphatically to 12 patients with advanced cancer in a phase I
trial. Toxicity occurred in a profile similar to that seen with intravenous IL-2, and
no clinical response was achieved (Sarna et al., 1990). This toxicity may have
contributed in modulating the proliferation of H238 cells in response to human IL2.

198

Our in vivo studies focused on the evaluation of IL-2 transfected and
antisense transfected H238 cells on tumorigenicity in the BALB/c murine host.
H238 cells stably transfected with IL-2 showed complete tumor regression (100%
tumor free) when compared to mice injected with tumor cells transfected with
antisense TGF-p (Fig 29). BALB/c mice injected with H238 cells transfected with
a control plasmid or wild type H238 cells showed tumor incidence in
approximately 80-100% of the animals. Splenocytes obtained from tumor bearing
and non-tumor bearing mice showed distinct differences in their SI values.
Lymphocytes from mice injected with antisense transfected H238 cells or IL-2
transfected H238 cells (non tumor bearing) showed significantly higher SI values
then splenocytes from tumor bearing mice (control or H238 inoculated),
indicating greater immune capacity (Fig 31 and 32). In murine models, the
therapeutic efficacy of IL-2 against several histologically distinct tumors is
mediated predominantly by host-derived CD8+ T cells (Ke et al, 1998).
A combination therapy of mice with established metastases with
intraperitoneal injections of anti-TGF-p antibody, together with IL-2 resulted in a
significant decrease in the number of tumor lesions whereas in a nude mouse
model challenged with a human carcinoma tumor, no significant decrease could
be found after therapy with IL-2 or anti-TGF-p antibody alone (Wojtowicz-Praga,
1997). The idea behind this combination therapy was to abolish the
immunosuppression induced by TGF-p and stimulate the lymphocytes with IL-2.
This combination therapy approach is an attractive strategy for clinical use and in
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addition, circumvents several limitations of the clinical application of systemic IL2 therapy.
Alteration of TGF-p signaling pathways underlies a wide variety of human
disorders (Reiss, 1999). The TGF-p receptors and signaling pathway have been
shown to comprise a tumor suppressor pathway in carcinogenesis, and many
investigators believe that development of resistance to TGF-p by tumor cells
represents a key event in the progression of malignancy. It is known that TGF-p
receptors are inactivated in many human malignancies by somatic mutation,
gene deletion, or transcriptional repression (Markowitz et al., 1995; Hahm et al.,
1999). Since the hypothesis that defects in the TGF-p receptor system might
contribute to the development of resistance to the growth-inhibitory effects of
TGF-p was first introduced (Sporn and Roberts, 1988), correlations between
resistance to growth inhibition by TGF-p and the lack of TGF-p receptor
expression have been reported in a variety of different human cancer cell lines,
including gastric and colon cancer cells, leading to the suggestion that the
development of such TGF-p resistance represents a significant step in the
process of carcinogenesis (Sun et al., 1994; Reiss, 1997). Inactivation of the
TGF-p receptor genes or components of its signal transduction mechanisms
leading to the development of resistance to TGF-p represent relatively late
events in the process of carcinogenesis and may make a key contribution to the
transition from late adenoma to malignancy.
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There are several mechanistic approaches that have been identified as
causes for the non-responsiveness of tumor cells to TGF-(3. The first direct
evidence that resistance to TGF-p can develop through the acquisition of a
mutation in a receptor gene came with the discovery that a majority of gastric
cancer cell lines studied were resistant to the growth inhibitory effects of TGF-p
and that this resistance correlated with gross structural defects of the TGF-p Rll
gene (Park et ai, 1994). This is prominently observed in gastric cancer. The
mRNA of the type II receptor encodes a truncated receptor only 97 amino acids
in length, whereas the full length receptor is 567 amino acids. Thus, the
truncated receptor was predicated to lack exon 4, 5, 6,and 7 which are part of the
serine/threonine kinase domain, disabling it from transducing any TGF-p signals
(Liu etai, 1995). In addition, other mutant variants have been found which have
exons 1,2 and 3 and also contain the 51-152 core binding domain but do not
have the ability to transduce TGF-p signaling. These receptors often act as
dominant negative mutants, as co-transfection of functional receptors resolves
signaling as shown by TGF-p-inducible luciferase reporter constructs (Issa,

1994}.
A major breakthrough in understanding mutagenesis of the TGF-p Rll
occurred with a specific subpopulation of human colon cancers, termed
hereditary non-polyposis colon cancer (HNPCC), a familial cancer syndrome
characterized by a high incidence of colon, endometrial and gastric cancers. A
characteristic feature of these tumors is a defect in DNA replication error repair
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mechanism leading to the phenomenon of microsatellite instability and what has
been termed the replication error repair positive (RER+) phenotype (Aaltonen et
al., 1993; Eshleman and Markowitz, 1995; Parsons etai, 1995). Defective DNA
repair in these tumors is highly correlated with mutations of the TGF-pRII gene.
The characteristic finding is a frameshift mutation affecting a ±10 base pair
polyadenine repeat (BAT-RII) that is present in the TGF-pRII coding region
(codon 125± 128) (Parsons et al., 1995; Lu etal., 1995; Lu et al., 1996). Insertion
or deletion introduces early stop codons and encodes the truncated TGF-pRII
proteins, which are 129 to 161 amino acids in length in contrast to the wild type
length of 565 amino acids and lacking the activating serine/threonine kinase
domain. The BAT-RII mutations are commonly found in gastric carcinomas with
microsatellite instability that exhibited intestinal type histology and colon cancers.
They are rare, however, in sporadic gastric (Shitara et al., 1998), hepatocellular
(Salvucci etal., 1999; Kawate etal., 1999), breast (Tomita et al., 1999;
Takenoshita et al., 1998), pancreatic (Vincent et al., 1996) and pituitary
carcinomas (DAbronzo et al., 1999).
Numerous other malignancies examined posses reduced or undetectable
levels of receptors for TGF-p. Several lines of evidence suggest that
transcriptional repression of the TGF-p Rll gene may be another major
mechanism to inactivate TGF-p Rll. In many cancers without mutation of the
receptors, reduced immunoreactivity and decreased mRNA level were clearly
demonstrated, which indicates that other mechanisms might also be involved in
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inactivating the expression of TGF-p Rll. Methylation of CpG islands in the
promoter regions of various genes is one established mechanism for regulating
transcriptional activity (Bird, 1986). Recent study has demonstrated that DNA
methylation is also involved with repression of TGF-p Rll expression in estrogen
receptor-positive breast cancer cells (Ammanamanchi et ai, 1998).
However, given that both TGF-p Rl and Rll are equally essential for TGFp signal transduction, mutations in either gene might yield equivalent non
functional results. The absence of a simple repetitive nucleotide sequence in the
TGF-p Rl gene presumably makes it less susceptible to mutation as a result of
defects in DNA repair (Kim et al., 1996). Gross structural abnormality in the TGFPRI gene has been observed using Southern blot analysis of a TGF-p resistant
human prostate cancer cell line (Kim et al., 1996).
The second part of this project attempted to investigate the lack of H238
responsiveness to the growth modulatory effects of TGF-p. Previous studies by
Uhm et al, showed that H238 cells were refractory to TGF-p (Gridley et al.,
1993). To confirm these studies, the growth kinetics of H238 cells was measured
in the presence of varying amounts of TGF-p. There was no observable
difference in the growth of H238 cells with or without the presence of TGF-p (Fig.
27). RT-PCR amplification products of different segments of type I and type II
receptor mRNA, revealed no apparent large mutations after sequence analysis.
Protein expression was verified using western blot analysis. H238 cell lysate was
resolved into a cytosolic and membrane fractions and probed for either type I or
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type II receptors. Receptor localization and quantitation was studied using laser
scanning microscopy. Results from both of these studies indicate that the
receptors are expressed in the H238 cell line. However, it was interesting to note
that the expression of the type 2 receptor was lower than the type I receptor as
shown by ICC and LSC data. A subset of a human gastric cancer cell line found
to be insensitive to TGF-p, expresses low levels of TGF-pRI mRNA relative to
other cohorts which are highly responsive to TGF-p. Despite this low level of
TGF-pRI expression, these cells are resistant to the growth inhibitory effects of
TGF-p, suggesting that an appropriate ratio of TGF-pRI and TGF-pRII may be
required for the TGF-p signaling (Kang ef a/., 1999). This could partly explain the
inert nature of the H238 cells. In addition, cross linking studies between ligand
and receptor may shed more light on this fundamental question.
The presence of mRNA and protein for both TGF-pRI and TGF-pRII in the
H238 cell line suggests that the defect in these cells is unlikely the result of
inefficient transcription or translation but may instead represent a defect in
protein processing/trafficking by which H238 cells escape effects of TGF-p within
the TGF-p-rich microenvironment of the tumor. There have been only a few
instances in which loss of cell surface expression of TGF-pRI or TGF-pRII has
not been accompanied by transcriptional down-regulation of the receptor gene.
DeCoteau et al. (1997) showed that primary tumor cells from several patients
with chronic lymphocytic leukemia had become refractory to inhibition by TGF-p
because of loss of TGF-pRI expression, although mRNA of the expected size for
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TGF-pRI were found in these cells. Similarly, it has been proposed that the TGFp resistant MCF-7 breast cancer cell line, which does not display surface TGFpRII but has cytosolic TGF-pRII protein, may have a pH defect compromising the
regulation of endosome acidification and impeding trafficking of the receptors to
the cell surface (Koli ef a/, 1997). Finally, Knaus et al. (1996) identified a
dominant negative TGF-pRII in a cutaneous T cell lymphoma, which is coded for
by one allele and can oligomerize with the wild-type TGF-pRII, preventing it from
reaching the cell surface. The abundance of evidence provides strong support for
the potential of receptor abnormalities as a likely cause for inactivity of H238 cells
to TGF-p.
Tumors, such as adenocarcinomas of the colon, appear to escape from
regulation by TGF-p by a variety of mechanisms, including microsatellite
instability (Markowitz et al., 1995) and mutation of Smad signaling intermediates
(Shi et al., 1997). It recently has been demonstrated in Mv1Lu epithelial cells that
the metabolic half-lives of TGF-pRI and TGF-pRII are substantially different
(Wells et al., 1997). Treatment with TGF-p was shown to reduce the stability of
the Golgi-processed forms of both receptors, implying the existence of metabolic
regulatory mechanisms in response to autocrine or paracrine TGF-p. Both
receptors are highly glycosylated, and it has been observed that altered
glycosylation may affect turnover and degradation of the receptors (Koli and
Arteaga, 1997). Two differentially glycosylated forms of TGF-pRII have been
identified in cytoplasmic and membrane fractions from Mv1Lu CCL-64 cells and
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the MDA-231 breast cancer line, both of which express receptors, whereas only
the cytoplasmic form was present in the TGF-pRII cell surface-deficient MCF-7
breast carcinoma line mentioned above (Koli and Arteaga, 1997). The existence
of such vaired forms of receptors further strengthens the possibility that such
deformalities may be present in the H238 cells.
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CONCLUSION
This project was directed at an attempt to develop a modality to control
and abrogate H238 tumor development in the BALB/c host. Previous studies
conducted in our laboratory made use of therapeutic regimens ranging from
modification in dietary intake to systemic applications of cytokine and
immunotherapeutic agents. The advent of non-viral gene therapy techniques has
presented a novel strategy to attack cancer. The effectiveness and elegance of
DNA based techniques is derived from low toxicity, targeted administration,
induction of long lasting immunity, stability and their ability to induce cytotoxic T
cells unlike conventional vaccines. Bearing these principles in the forefront of our
design, we sought to investigate the anti-tumor potential of H238 tumor cells
engineered to express murine IL-2. To augment this strategy, we utilized an
antisense modality to reduce expression of the immunosuppressive cytokine,
TGF-p, which is expressed by the H238 tumor.
Our preliminary studies were conducted to verify expression of TGF~pi. In
addition we discovered that the H238 cell line expresses TGF~p2 and TGF-p3. In
vitro expression studies demonstrated that H238 cell transfected with IL-2
expression plasmid produced biologically significant amounts of IL-2 in
comparison to either wild or plasmid control H238 cells. The IL-2 transfected cells
exhibited no evidence of toxicity, as determined by microscopic analysis and
MTS proliferation assays. H238 cells transfected with the antisense TGF-p
expressing construct, showed a 5-fold reduction in TGF-p production; again, in
comparison to wild type and control H238 cells. Previous studies conducted by
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Mao et a/(1995), showed that H238 proliferation was inhibited in the presence of
high exogenous concentration of human IL-2. To verify this, we modified their
procedure and used murine IL-2 to investigate if, indeed, there was any change
in the proliferation. In addition, we also used lower concentrations of IL-2, which
reflected approximate physiological concentrations found in our in vivo model.
Our results clearly show that murine IL-2 does not inhibit the growth of H238 cells
in vitro. To quell concerns that our transfected plasmids may affect the growth of
our engineered cells in comparison to the wild type cells, we measured the
growth kinetics of wild type and engineered H238 cells. We observed no change
in these kinetics, essentially allaying any concerns of plasmid growth modulation.
Having successfully shown that H238 cells can be genetically engineered
to express IL-2 and reduce TGF-p production, the experiment was extended to
our in vivo BALB/c model. In a series of three different runs, groups of BALB/c
mice were injected s.c. with either H238, plasmid control H238, H238-IL2 or
masH238 cells. The tumorigenicity of these cells was evaluated by measuring
tumor growth, upon formation of palpable tumors. During the course of these
experiments, mice injected with H238 and control pcH238 cells displayed a 100%
incidence of tumorigenicity. Mice injected with H238-IL2 cells were almost tumor
free and the group injected with masH238 cells showed small tumor growth. The
difference between the later and former groups was statistically significant in all
experimental runs, confirming our hypothesis that either a reduction of TGF-p or
IL-2 expression would induce a potent anti-tumor response. Immune activity was
measured by harvesting splenocytes from these animals and measuring their
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proliferation by stimulation with different pre-titrated mitogens; PHA, Con A and
IPS. These mitogens stimulate proliferation of different lymphocyte populations.
The SI values calculated from these results demonstrate that lymphocytes
obtained from small/non tumor bearing mice have higher values then tumor
bearing animals. This provides evidence that an immunological component does
indeed play a part in the anti-tumor effect generated, and this effect seems to be
greatly enhanced in non-tumor bearing animals (injected with H238-IL2 or
masH238 cells).
An interesting question was raised during the course of these experiments
whether, expression of high levels of TGF-p by the H238 cells had no effect on
H238 growth modulation. Previous studies done by Mao et al (1995) had shown
this. This experiment was repeated to verify and confirm those results. H238 cells
were grown with different concentrations of TGF-pi in the cell culture medium,
and proliferation was measured and compared to cells grown with normal
complete media. The results unequivocally showed that H238 cells were non
responsiveness to TGF-p. Studies conducted by other laboratories have shown
that disruption of the TGF-p signaling pathway is easily disrupted by mutation or
repression of the type 2 receptor. Messenger RNA transcripts for Type 1 and
Type 2 receptors were amplified from total RNA extracted from H238 cells.
Amplified products were purified, submitted for sequencing and thereafter,
analyzed using BLAST and compared to published sequences in Genbank. No
mutations were identified and sequence identities matched 100%. The next step
involved confirmation of receptor protein expression. Western blot analysis of
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whole cell lysate demonstrated that both type 1 and type 2 receptors are
expressed. Resolution of the lysate into membrane and cytosolic fractions
corroborated the earlier results, the receptors being present in both fractions.
Localization studies using immunocytochemistry showed that the type 2 receptor
having a more cytosolic distribution, however, due to the low number of receptors
per cell (200/cell) it might not be prudent to rely on these entirely. To verify these
results, both type 1 and type 2 receptors were quantified using the Laser
Scanning Cytometer. After multiple runs to optimize the assay, our results show
that the type 2 receptor was 50% lessabundant than the type 1 on H238 cells.
This difference may partly explain the inert nature of H238 cells to TGF-p.
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FUTURE EXPERIMENTS
The H238 cell line was created by infection of 238 embryonic cells with
UV-inactivated HSV-2 virus. This virus has been shown to influence the
oncogenic potential of cells by disrupting key signaling events. Early studies
using immunocytochemistry showed that HSV tumor proteins were detected in
the nucleus; however, none were detected in the cytosol. A confirmation study to
verify those results would provide clues as to which signaling pathway was being
affected due to the presence of the virus. In addition, these modifications to
signaling may answer the all important question, what mechanism is involved in
facilitating the constitutive high level expression of TGF-p by these cells.
TGF-p has been shown to facilitate metastasis by promoting anchorage
independent growth in a variety of carcinomas, both human and murine.
Expression of this potent immunosuppressive cytokine by the H238 cells has
been verified conclusively. We have currently been implanting tumors s.c. into
BALB/c mice and measuring tumor growth. It would be interesting to investigate
the viabiliity of this fibrosarcoma if grown in conditions where the cells remain in
suspension. Preliminary studies using our soft agarose technique has shown that
the H238 cells can be successfully propagated as clumps in DMEM media with
agarose. In vivo studies to measure spleen cell proliferation can be extended to
include analysis of tumor metastasis in tissues such as the lungs, liver and
kidney.
To successfully abrogate the H238 tumor, an enhanced modality needs to
be designed to further reduce expression of TGF-p. Using this project as a
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stepping stone, having shown that antisense TGF-pi can effectively reduce TGFpi and that the H238 cell do express TGF-p2 and TGF-p3, it would be prudent to
have a better antisense design. An effective antisense modality would have to be
aimed at available ‘open’ sites in the mRNA’s of all 3 isoforms. Finding
homologous sequences between the 3 isoforms and using online software to
predict RNA secondary structure could easily achieve this. In addition, the
antisense oligonucleotides can be designed to include a phosphothriaonate
backbone, to enhance delivery and stability of the antisense bullet.
In addition, there have been great strides in the discovery of other
cytokines that have been shown to play an important role in immunosuppression.
One of most studied cytokines in this arena after TGF-p, is IL-10. This cytokine is
expressed by murine Th2 cells and plays an important role in controlling immune
proliferation by inhibiting IL-2, IFN-y and TNF-a mediated responses. A recent
study has shown that IL-10 may be expressed in a glioma cell line (Kjellman et
al, 2000). It would be interesting to adopt these primers and investigate the
expression of IL-10 from the H238 cell line. To date, there is no evidence
showing that IL-10 can be expressed from a fibrosarcoma, and if shown to be
positive this may be the first such case.
The immunotherapy approach used in this project can be modified to
include other potent cytokines. IL-12 and IFN-y, have been shown to be potent
inducers of strong anti-tumor responses. In addition, systemic administration of
these lymphokines, cause less toxicity then IL-2. Delivery of these cytokines can
also be modified to achieve more stronger and more stable expression. Viral
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vectors such the vaccina virus, or adeno or adeno-associated virus can be
utilized in order to achieve these goals. These vectors could also be used to
deliver genes that may help elucidate the inert nature of H238 cells to TGF-p.
The TGF-p/TGF-p receptor interaction could also be investigated.
Exogenous TGF-p could be cross-linked to the endogenous receptors on the
H238 cells and co-IP’ed. The IP product could then be processed on an
immunoblot to probe for the co-IP’ed product. This would provide tentative
evidence that there was interaction/binding between ligand and receptor. The
signaling pathway could also be further dissected using RT-PCR with specific
primers. Amplified products could then be sequenced to verify their identity and
confirmed to be mutation free using BLAST. Functional analysis of the signaling
pathway could also be investigated. Transfecting H238 cell with reporter
plasmids using either the PAM or the cylclin D promoter with a luciferase
cassette could show if there were any signal transduction events from the
receptor. Another important advantage of using these constructs would be to
shed light on the positive or negative proliferation of FI238 cells by TGF-p.
Luciferase expression from the reporter with the PAM promoter would be
activated if the signal resulted in positive proliferation, the cylclin D promoter
would be activated only if the signal resulted in negative proliferation.
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